

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>


# **BMJ Open**

## CRYOTHERAPY ASSOCIATED WITH TAILORED LAND-BASED EXERCISES FOR INDIVIDUALS WITH KNEE OSTEOARTHRITIS: A PROTOCOL FOR A RANDOMIZED TRIAL

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-035610
Article Type:	Protocol
Date Submitted by the Author:	07-Nov-2019
Complete List of Authors:	Ogura Dantas, Lucas; Federal University of Sao Carlos, Physiotherapy Jorge, Ana Elisa; Federal University of Sao Carlos, Physiotherapy Serrao, Paula; Federal University of Sao Carlos, Physiotherapy Sendín, Francisco; Universidad de Córdoba, 2Sociosanitary Sciences, Radiology and Physical Medicine, University of Córdoba, Córdoba, Spain and Instituto Maiomónides de Investigación Biomédica de Córdoba (IMIBIC) Salvini, Tania; Federal University of Sao Carlos, Physiotherapy
Keywords:	PAIN MANAGEMENT, REHABILITATION MEDICINE, PUBLIC HEALTH
	·

SCHOLARONE <sup>™</sup>	
Manuscripts	

BMJ



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**TITLE:** CRYOTHERAPY ASSOCIATED WITH TAILORED LAND-BASED EXERCISES FOR INDIVIDUALS WITH KNEE OSTEOARTHRITIS: A PROTOCOL FOR A RANDOMIZED TRIAL

Lucas Ogura Dantas<sup>1</sup>, PT; Ana Elisa Serafim Jorge<sup>1</sup>, PT, MSc, PhD; Paula Regina Mendes Silva Serrao<sup>1</sup>, PT, MSc, PhD; Francisco Alburquerque-Sendín<sup>2</sup>, PT, MSc, PhD; Tania Fatima Salvini<sup>1</sup>, PT, MSc, PhD.

Author Affiliations: <sup>1</sup>Physical Therapy Department, Federal University of São Carlos, São Carlos, Brazil. <sup>2</sup>Sociosanitary Sciences, Radiology and Physical Medicine, University of Córdoba, Córdoba, Spain and Instituto Maiomónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain. <sup>3</sup>Physical Therapy Division, University of Brasilia, Brasília, Distrito Federal, Brazil.

**Corresponding Author:** Tania Fatima Salvini, PT, MSc, PhD. Neuromuscular Plasticity Laboratory, Physical Therapy Department, Federal University of São Carlos, Rodovia Washington Luiz, Km 235, CEP:13.565-905, CxP: 676, São Carlos, SP, Brazil (tania@ufscar.br)

## ABSTRACT

Introduction: There is an unmet need to develop new strength therapeutic exercises (STE) protocols using different treatment durations, frequencies, modalities, and intensities for individuals with knee osteoarthritis (KOA). Cryotherapy has been widely used as adjunct treatment for clinical improvement in individuals with KOA due its effects on pain and inflammation process. However, there are still disagreements in its recommendation by some prestigious KOA guidelines. The aim of this study was to verify the complementary effects of cryotherapy when associated with a STE protocol on patients with KOA. Methods and analysis: Placebo-controlled randomized trial with concealed allocation and intention-to-treat analysis. A baseline assessment will be performed before the 8-week intervention period, and a post-intervention assessment right after the last session. To check for residual effects of the interventions applied, a three- and a sixmonth follow-up will be performed. Participants will be people living in the community with KOA. There will be three groups: (1) the experimental group that will receive a tailored STE protocol and after, a cryotherapy session of 20 minutes; (2) the sham control group that will receive the same regimen but with sham packs filled with sand; and (3) the active treatment control group that will receive only the STE protocol. The primary outcome will be pain intensity according to a visual analogue scale. Secondary outcomes will be changes according to the Western Ontario & McMaster Universities Osteoarthritis; the Short-Form 36 questionnaire; the 30-Second Chair Stand Test; the Stair test; and the 40-meter fast paced walk test. Ethics and dissemination: The trial was approved by the Institutional Ethics Committee of Federal University of Sao Carlos, São Paulo, Brazil. Registration approval number: CAAE: 65966617.9.0000.5504. The results will be expected to be published in peer-reviewed journals.

## Trial registration number: NCT03360500

## Strengths and limitations of this study:

- The trial will be conducted following well-established reporting guidelines to improve the evidence synthesis regarding this topic. The methodology is designed to minimise bias by including concealed treatment allocation, and blinding of the outcome assessor and biostatistician.
- Participants will present radiographically confirmed knee osteoarthritis and a sufficient level of pain to ensure ample scope for improvement.
- The therapist who will deliver cryotherapy or the placebo intervention, and the patients will not be blinded. Although this may have resulted in bias, given the study design, a method of blinding patients and therapists to thermal agents has yet to be established.

Page 5 of 32

## **BMJ** Open

Knee osteoarthritis (KOA) is a serious disease with a high societal and economic burden,<sup>1</sup> affecting approximately 250 million people worldwide.<sup>2</sup> Current clinical practice guidelines recommend a combination of pharmacological<sup>3</sup> and non-pharmacological<sup>4</sup> treatment strategies to manage KOA symptoms, and to improve patient's quality of life (QoL). However, pharmacological treatment options remain limited, poorly tolerated, with frequent toxicities,<sup>5,6</sup> and misused by patients.<sup>7</sup>

Physical Therapy, specifically the use of strength therapeutic exercises (STE) protocols, is a wellestablished treatment for KOA, since it can relieve pain, reduce stiffness, improve physical function, and ultimately ameliorate quality of life.<sup>1,8</sup> There is high-quality evidence demonstrating that the benefits of STE protocols for pain and quality of life are sustained for at least two to six months after the end of a treatment for individuals with KOA<sup>8</sup>. Therefore, there is no need for new studies to demonstrate the effectiveness of STE for KOA patients.<sup>9</sup> However, there is a call for further research to develop novel insights within STE protocols regarding different treatment durations, frequencies, modalities (types), and intensities.<sup>10</sup> The majority of the current protocols have low exercise adherence and are substantially under-utilized by KOA patients mainly due to their beliefs, socioeconomical barriers, fear of movement, and early treatment pain aggravation.<sup>11,12</sup> These barriers create an unmet need for science-based STE protocols that are tailored and cost-effective for KOA patients and that can help clinicians to target rehabilitation.

Associated with therapeutic exercises, many physical modalities such as thermal agents, laser therapy, therapeutic ultrasound, and electrical stimulation have been used as adjunct treatments for clinical improvement in individuals with KOA.<sup>4,13</sup> Cryotherapy, a non-pharmacological intervention, has been widely used in some rheumatic joint diseases<sup>14,15</sup> for its effects on pain,

inflammation and oedema.<sup>16,17</sup> It is considered safe, inexpensive, and easy to administer for healthcare professionals and patients. Moreover, it can be prescribed in isolation or as a complementary treatment<sup>15</sup>, and seems to be well accepted by KOA individuals.<sup>18,19</sup> However, altough cryotherapy is recommended as a treatment option by some international KOA guidelines,<sup>20,21</sup> others found insufficient evidence to support it.<sup>22–24</sup> Mainly due to methodological limitations, relevant systematic reviews conclude that further trials are needed to evaluate cryotherapy effects on pain, function, and quality of life in individuals with KOA.<sup>17,25,26</sup>

In this study, we aim to design a randomized trial to verify the complementary effects of cryotherapy associated with a tailored STE protocol intervention for pain, function, and quality of life in individuals with KOA. The proposed trial will contribute with new evidence to target KOA rehabilitation, help pain management, and thereby improve physical function and quality of life of these patients. The STE protocol described on this study was developed by our research group and was also used in another randomized trial testing the complementary effects of low-level laser therapy in individuals with KOA (trial registration number: U1111-1215-6510).

#### **METHODS**

To report this study protocol, we followed the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT),<sup>27</sup> the Osteoarthritis Research Society International clinical trials recommendations: design, conduct and reporting of clinical trials for knee osteoarthritis,<sup>28</sup> and the Template for Intervention Description and Replication checklist (TIDieR).<sup>29</sup> The randomized trial developed using this protocol, will be reported according to the Consolidated Standards of

#### **BMJ** Open

Reporting Trials (CONSORT) statement for randomized trials of non-pharmacologic treatments.<sup>30</sup> The trial is registered on clinicaltrials.gov (NCT03360500) platform.

## Study design and setting

This will be a placebo-controlled randomized clinical trial. A baseline assessment (A1) will be performed on the weekday before the 8-week intervention period, and a post-intervention assessment (A2) right after the last session. To check for residual effects of the interventions, a three-month (A3) and six-month (A4) follow-up assessment will be performed. Each patient will be assessed in the same period of the day in a physiotherapy research laboratory by the same assessor. To reduce bias, the therapists responsible for applying the intervention and the outcomes assessor will follow standardized scripts to give explanations regarding the general objective of the study.<sup>28</sup> Moreover, prior to the beginning of the study, the therapists responsible for the intervention will participate in a 10-hour training module, which will consist of scientific information and clinical training regarding KOA, the STE protocol, and the use of the cryotherapy. Intervention adherence, medication intake and adverse events will be tracked with an 8-week assessment diary given to the participants at baseline assessment and with a 12-week assessment diary for the three-month follow-up assessment. All the participants will be advised to not practice any other type of regular physical exercises during the study protocol that could interfere with the STE protocol. A verbal and written explanation of the objectives and methodology of the study will be provided to all the participants, and those willing to participate will sign a written informed consent form, approved by the local ethics committee. A detailed timeline of the trial is presented on Table 1.

## **Patient and Public Involvement**

The patients and public were not involved in planning and design of this study.

## **Participants**

 Participants will be recruited through public announcements on social media, advertisements via local news, University community newsletters, and banners or leaflets posted at strategic locations at the city. People who express interest in participating in the study will undergo first a screening process to check eligibility criteria, and after a lateral, anteroposterior, and axial radiography of both knees to determine KOA severity. All individuals will be classified with KOA based on the clinical and radiographic criteria of the American College of Rheumatology.<sup>31</sup> Participants will be required to have symptoms and a radiographic grade (Kellgren and Lawrence scale) of  $\geq 2$  (at least mild radiographic OA) in at least one knee compartment.<sup>28</sup> To be included in the study, participants will also need to: be aged between 40 and 75 years; be engaged in less than 45 minutes/week in accumulated physical activity of at least moderate intensity<sup>32</sup>; have a body mass index <35 kg/m<sup>2</sup>; and pain intensity in the prior week of  $\geq 4$  cm on a 10-cm visual analogue scale.<sup>28</sup> Exclusion criteria will comprise: physical therapy in the prior 3 months; intra-articular knee injections in the prior 6 months; medical restrictions such as cardiorespiratory, neurological or any other rheumatology conditions; previous hip, knee or ankle surgery; and any other chronic condition that leads to chronic pain or dysfunction. All the participants will be asked to provide a medical certificate stating to be healthily able to perform physical activities.

### **BMJ** Open

## Interventions

The interventions will be administered by physical therapists in the physiotherapy clinic of the university. The sessions will last 90-minutes and will take place over a period of eight weeks, three times per week in nonconsecutive days, totaling 24 sessions. All the participants will perform the STE protocol and after, according to the random allocation, cryotherapy or sham will be administered in individual rooms for each patient.

### STE protocol

The 8-week land-based supervised exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for KOA.<sup>33,34</sup> The STE protocol characteristics are described in **Figure 1** and a detailed description of all the exercises is presented in the **Supplementary file** of this protocol. The protocol is divided into two cycles. Each cycle consists of 4 weeks of progressive exercises, with tailored intensity for each participant, that is performed 3 times per week in non-consecutive days, with 24 hours rest between sessions. The first session is used to demonstrate and explain the STE protocol, and to perform an exercise familiarization using no loads by the participants. The second session is destined to estimate the initial resistance of each participant for each exercise. The volitional interruption method is used in order to achieve the benefits of a resistance training and to provide a low risk of musculoskeletal injuries to the participants. <sup>35</sup> The loads are gradually increased until the participant is able to adequately perform 12 repetitions with no voluntarily interruption due to muscle fatigue.

The STE protocol sessions consist of three phases. The first phase is a 10-minute warm-up in which the patients can choose, according to their preferences, to walk in a comfortable intensity in

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

an outdoor circuit, treadmill or ride in a stationary bicycle. The second phase consists of 40 minutes of strengthening exercises (resistance training), such as lower limb, trunk muscles, and neuromuscular training involving balance exercises. The third phase is a cool-down phase, consisting of static stretching exercises to potentially reduce musculoskeletal injuries and to maximize the benefit of the STE protocol.<sup>36</sup> To ensure patient safeness, cardiac and respiratory frequencies and blood pressure are monitored at the beginning of each session or if the participant presents an intense rate of perceived exertion according to the Borg scale while performing an exercise.<sup>37,38</sup>

## Cryotherapy protocol

To apply cryotherapy, the therapist will explain to the patient that the intervention will consist of crushed ice applied to the more-affected knee for 20 minutes. Participants will be positioned in dorsal decubitus with both legs extended and relaxed. To protect the skin from possible frostbite, the entire knee surface will be covered with a moist surgical gauze ( $45 \times 50 \times 0.01$  cm). Next, two plastic bags ( $24 \times 34 \times 0.08$  cm), each containing 1 kg of crushed ice, will be placed on the knee, covering the anterior, posterior, medial and lateral surfaces. A comfortable, non-painful compression will be applied over the ice packs by wrapping an elastic bandage around them, and the therapy will be left in situ for 20 uninterrupted minutes. The main purposes of compression is to maintain the ice packs in position on the knee<sup>39</sup> and to enhance cryotherapy effects.<sup>40</sup> For the cryotherapy sham intervention, the bags will be filled with 1 kg of dry sand instead of ice.

explanation about the intervention will be changed to mention 'application of sand packs' instead

The sand bags will be applied according to the same regimen in the same locations. The therapist's

#### **BMJ** Open

of 'cryotherapy application'. The sand packs will be applied with the same gauze underneath and the same bandage for compression.

## **Outcome measures**

All the outcomes will be measured by the same blinded assessor before and after the intervention, and at the 3- and 6-month follow-up periods. **Table 2** describes the main outcome measures that will be included on the trial and the recommended estimate of the minimum clinically important difference (MCID) for each outcome measure. We will measure pain intensity, knee subjective and objective physical function, and quality of life.

#### Primary outcome

The primary outcome will be pain intensity at rest assessed with a visual analogue scale. This selfreported pain score is a valid and reliable measure for KOA.<sup>41</sup> The visual analogue scale will be administered at baseline, on the final assessment day, and at the 3- and 6-months follow-up periods.

#### Secondary outcomes

To subjectively assess physical function and associated problems the Western Ontario & McMaster Universities Osteoarthritis (WOMAC) will be used. The Short-Form 36 (SF-36) questionnaire will be used to asses quality of life. Three objective physical function tests will also be used: The 30-Second chair stand test, the stair test, and the 40-meter fast paced walk test.

## Randomization

 Eligible patients who consent to participate will be randomly allocated into 3 groups of 40: (1) active control group that will receive the STE protocol only, (2) STE + cryotherapy group, and (3) STE + sham cryotherapy group. Random allocations will be determined by a computer-generated random numbers program and matched for gender (20 men and 20 women in each group). Allocation will be concealed, and the random allocations will be placed in opaque sealed envelopes that will be locked in a central location. Each participant's random allocation will be revealed just before the intervention start.<sup>28</sup>

## Sample size

We aimed to detect a minimum clinically important differences (MCID) of 1.75 cm units on the visual analogue scale.<sup>42</sup> In addition, we aimed to detect an MCID of 30 points on the WOMAC global score.<sup>43</sup> Calculations were based on an analysis of covariance adjusting for baseline outcome scores, assuming between-patient standard deviations of 2.0 cm for pain and 45 points for WOMAC global score. Based on these criteria, to achieve a significance level of 0.05 and a power of 0.80%, 37 participants with KOA were required in each group. To allow possible dropouts during the intervention period, 40 participants were recruited per group.

## Data analysis

The analyses will be performed by a blinded biostatistician using commercial software. The Kolmogorov-Smirnov test will be applied to evaluate the normality of data distribution. If the distribution is not normal, non-parametric tests will be used. For normal distributions, a 2-factor analysis of variance (ANOVA) will be conducted for the primary outcome (visual analogue scale

## **BMJ** Open

for pain) and secondary outcomes, with time (baseline, post-intervention, and follow-up) as the within-subject factor and group (STE, STE + cryotherapy, STE + sham cryotherapy) as the between-subject factor. In addition, tukey's test will be used for post-hoc analysis when necessary and an intention-to-treat analysis will be performed for all randomized participants. All the missing data will be replaced using the expectation maximization method. Between-group differences and their 95% confidence intervals will be reported and interpreted against the nominated thresholds for MCID. For outcomes where the MCID are not nominated, Cohen's d coefficient will be calculated to aid interpretation. An effect size greater than 0.8 will be considered large, around 0.5 moderate, and less than or equal to 0.2, small<sup>44</sup>. n or com

## ETHICS AND DISSEMINATION

All participants will provide written informed consent following verbal and written explanation of the study protocol and the opportunity to ask questions. Participants are free to withdraw from the trial at any time without prejudice to future treatment. Results will be presented at scientific meetings and published in peer-reviewed journals. All publications and presentations related to the study will be authorized and reviewed by the study investigators.

## TRIAL STATUS

The trial is currently recruiting and is expected to be completed (including follow-up testing) by June 2020.

## **AUTHORS CONTRIBUTION**

L.O.D., A.E.S.J., P.R.S., F.A.S., and T.F.S. designed the study protocol. L.O.D. wrote the first draft of the manuscript and together with A.E.S.J., P.R.S., F.A.S., and T.F.S. revised and produced the final version. All authors have read and approved the final version of the manuscript. L.O.D. takes responsibility for the integrity of the work as a whole.

## FUNDING

LOD and AESJ were financially supported by Sao Paulo Research Foundation (FAPESP, Process numbers #2018/23705-3, and #2017/00062-7 respectively) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ # 401333/2016-7).

## 

## DISCLAIMER

The study funders have had no role in study design; collection, management, analysis and interpretation of data; writing of the report; or the decision to submit the report for publication, and do not own ultimate authority over any of these activities.

## **COMPETING INTERESTS**

All authors have completed a uniform disclosure form and declare no conflicts of interest

## **ETHICS APPROVAL**

The trial was approved by the Institutional Ethics Committee of Federal University of Sao Carlos, São Paulo, Brazil. Registration approval number: CAAE: 65966617.9.0000.5504. All participants will be asked to give written informed consent before data collection began. The trial will be conducted according to the Helsinki Statement.


## REFRENCES

- 1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet (London, England)*. 2019;393(10182):1745-1759. doi:10.1016/S0140-6736(19)30417-9
- 2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2163-2196. doi:10.1016/S0140-6736(12)61729-2
- 3. Mandl LA. Osteoarthritis year in review 2018: clinical. *Osteoarthr Cartil*. 2018;(xxxx):1-6. doi:10.1016/j.joca.2018.11.001
- 4. Collins NJ, Hart HF, Mills KAG. OARSI year in review 2018: rehabilitation and outcomes. *Osteoarthr Cartil*. 2018;0(0). doi:10.1016/j.joca.2018.11.010
- 5. Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain Misconceptions and Mitigation Strategies. *N Engl J Med*. 2016;374(13):1253-1263. doi:10.1056/NEJMra1507771
- 6. Deveza LA, Hunter DJ, Van Spil WE. Too much opioid, too much harm. *Osteoarthr Cartil*. 2018;26(3):293-295. doi:10.1016/j.joca.2017.12.003
- 7. Vowles KE, Mcentee ML, Siyahhan P, Frohe T, Ney JP, Goes DN Van Der. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain*. 2015;156(4). http://www.nejm.org/doi/10.1056/NEJMra1507771.
- 8. Fransen M, Mcconnell S, Ar H, M VDE, Simic M, Kl B. Exercise for osteoarthritis of the knee. *Cochrane Libr*. 2015;(1):1-144. doi:10.1002/14651858.CD004376.pub3.www.cochranelibrary.com
- Verhagen AP, Ferreira M, Vendel EAER De, et al. Do we need another trial on exercise in patients with knee osteoarthritis? *Osteoarthr Cartil*. 2019;27(xxxx):1266-1269. doi:10.1016/j.joca.2019.04.020
- Lee AC, Harvey WF, Price LL, et al. Dose-Response Effects of Tai Chi and Physical Therapy Exercise Interventions in Symptomatic Knee Osteoarthritis. *PM&R*. 2018;10(7):712-723. doi:10.1016/j.pmrj.2018.01.003
- Nicolson PJA, Bennell KL, Dobson FL, Van Ginckel A, Holden MA, Hinman RS. Interventions to increase adherence to therapeutic exercise in older adults with low back pain and/or hip/knee osteoarthritis: a systematic review and meta-analysis. *Br J Sports Med.* 2017;51(10):791-799. doi:10.1136/bjsports-2016-096458
- 12. Dobson F, Bennell KL, French SD, et al. Barriers and Facilitators to Exercise Participation in People with Hip and/or Knee Osteoarthritis. *Am J Phys Med Rehabil*. 2016;95(5):1. doi:10.1097/phm.00000000000448
- Oo WM, Thae Bo M. Efficacy of Physical Modalities in Knee Osteoarthritis: Recent Recommendations. *Int J Phys Med Rehabil*. 2016;04(03):3-4. doi:10.4172/2329-9096.1000e112
- 14. Demoulin C, Vanderthommen M. Cryotherapy in rheumatic diseases. *Jt Bone Spine*. 2012;79(2):117-118. doi:10.1016/j.jbspin.2011.09.016
- 15. Guillot X, Tordi N, Mourot L, et al. Cryotherapy in inflammatory rheumatic diseases: A systematic review. *Expert Rev Clin Immunol*. 2014;10(2):281-294. doi:10.1586/1744666X.2014.870036
- 16. Bleakley CM, Davison GW. Cryotherapy and inflammation: evidence beyond the cardinal signs. *Phys Ther Rev.* 2010. doi:10.1179/1743288X10Y.0000000014

1		
2 3	. –	
4	17.	Dantas LO, Moreira R de FC, Norde FM, Mendes Silva Serrao PR, Alburquerque-Sendín
5		F, Salvini TF. The effects of cryotherapy on pain and function in individuals with knee
6		osteoarthritis: a systematic review of randomized controlled trials. Clin Rehabil.
7		2019:026921551984040. doi:10.1177/0269215519840406
8	18.	Porcheret M, Jordan K, Jinks C. Primary care treatment of knee pain - A survey in older
9		adults. Rheumatology. 2007;46(11):1694-1700. doi:10.1093/rheumatology/kem232
10	19.	Denegar CR, Dougherty DR, Friedman JE, et al. Preferences for heat, cold, or contrast in
11		patients with knee osteoarthritis affect treatment response. Clin Interv Aging. 2010;5:199-
12 13		206. doi:10.2147/CIA.S11431
13	20.	Chae KJ, Choi MJ, Kim KY, Ajayi FF, Chang IS, Kim IS. National Institute for Health
15		and Care Excellence. Osteoarthritis: Care and Management. December 2014.
16	21.	Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012
17		recommendations for the use of nonpharmacologic and pharmacologic therapies in
18		osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-474.
19		doi:10.1002/acr.21596
20	22.	McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical
21	<i></i> .	management of knee osteoarthritis. Osteoarthr Cartil. 2014;22(3):363-388.
22 23		doi:10.1016/j.joca.2014.01.003
23	23.	Fernandes L, Hagen KB, Bijlsma JWJJ, et al. EULAR recommendations for the non-
25	23.	pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis.
26		2013;72(7):1125-1135. doi:10.1136/annrheumdis-2012-202745
27	24.	Brosseau L, Taki J, Desjardins B, et al. The Ottawa panel clinical practice guidelines for
28	24.	the management of knee osteoarthritis. Part two: Strengthening exercise programs. <i>Clin</i>
29		<i>Rehabil.</i> 2017;31(5):596-611. doi:10.1177/0269215517691084
30	25.	Brosseau L, Yonge K a, Robinson V, et al. Thermotherapy for treatment of osteoarthritis.
31 32	23.	
33	26	Cochrane Database Syst Rev. 2003;(4):CD004522. doi:10.1016/S0031-9406(05)60490-7
34	26.	King J, De G, Brosseau L, et al. A systematic critical appraisal for non-pharmacological
35		management of osteoarthritis using the appraisal of guidelines research and evaluation II
36	27	instrument. <i>PLoS One</i> . 2014;9(1). doi:10.1371/journal.pone.0082986
37	27.	Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard
38		Protocol Items for Clinical Trials. Ann Intern Med. 2013;158(3):200. doi:10.7326/0003-
39	•	4819-158-3-201302050-00583
40 41	28.	McAlindon TE, Driban JB, Henrotin Y, et al. OARSI Clinical Trials Recommendations:
41		Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthr Cartil.
43		2015;23(5):747-760. doi:10.1016/j.joca.2015.03.005
44	29.	Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template
45		for intervention description and replication (TIDieR) checklist and guide. BMJ.
46		2014;348(mar07_3):g1687. doi:10.1136/bmj.g1687
47	30.	Barbour V, Bhui K, Chescheir N, et al. CONSORT Statement for randomized Trials of
48		nonpharmacologic treatments: A 2017 update and a CONSORT extension for
49 50		nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47.
50 51		doi:10.7326/M17-0046
52	31.	Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and
53		reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and
54		Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis
55		Rheum. 1986;29(8):1039-1049. doi:10.1002/art.1780290816
56		
57		
58 59		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
~~		

- 32. Dunlop DD, Song J, Lee J, et al. Physical Activity Minimum Threshold Predicting Improved Function in Adults With Lower-Extremity Symptoms. *Arthritis Care Res*. 2017;69(4):475-483. doi:10.1002/acr.23181
  - Messier SP, Mihalko SL, Beavers DP, et al. Strength training for arthritis trial (START): Design and rationale. *BMC Musculoskelet Disord*. 2013;14(1):1. doi:10.1186/1471-2474-14-208
  - Fransen M, McConnell S, Harmer AR, Van Der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee: A Cochrane systematic review. *Br J Sports Med.* 2015;49(24):1554-1557. doi:10.1136/bjsports-2015-095424
  - 35. Nóbrega SR, Ugrinowitsch C, Pintanel L, Barcelos C, Libardi CA. Effect of Resistance Training to Muscle Failure vs. Volitional Interruption at High- and Low-Intensities on Muscle Mass and Strength. *J Strength Cond Res*. 2018;32(1):162-169. doi:10.1519/JSC.00000000001787
  - 36. Bennell KL, Dobson F, Hinman RS. Exercise in osteoarthritis: Moving from prescription to adherence. *Best Pract Res Clin Rheumatol*. 2014;28(1):93-117. doi:10.1016/j.berh.2014.01.009
  - 37. American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription for older adults with osteoarthritis pain: consensus practice recommendations. A supplement to the AGS Clinical Practice Guidelines on the management of chronic pain in older adults. *Jags*. 2001;49(6):808-823. doi:10.1046/j.1532-5415.2001.00496.x
  - 38. Vincent KR, Vincent HK. Resistance exercise for knee osteoarthritis. *PM R*. 2012;4(5 Suppl):S45-52. doi:10.1016/j.pmrj.2012.01.019
  - 39. Silva P, Lott R, Wickrama S, Mota J, Welk G. Elastic Bandaging for Orthopedic and Sports Injuries Prevention and Rehabilitation: A Systematic Review. *Int J Sport Nutr Exerc Metab.* 2016;32:1-44. doi:10.1123/ijspp.2015-0012
  - 40. Song M, Sun X, Tian X, et al. Compressive cryotherapy versus cryotherapy alone in patients undergoing knee surgery: a meta-analysis. *Springerplus*. 2016;5(1):1-12. doi:10.1186/s40064-016-2690-7
  - 41. Hawker G, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. *Arthritis Care Res*. 2011;63(SUPPL. 11):240-252. doi:10.1002/acr.20543
  - 42. Bellamy N, Carette S, Ford P, et al. Osteoarthritis Antirheumatic Drug Trials. III. Setting the Delta for Clinical Trials--Results of a Consensus Development (Delphi) Exercise. *J Rheumatol 19 (3)*, 1992;3:451-457.
  - 43. Fitzgerald GK, Fritz JM, Childs JD, et al. Exercise, manual therapy, and use of booster sessions in physical therapy for knee osteoarthritis: a multi-center, factorial randomized clinical trial. *Osteoarthr Cartil.* 2016;24(8):1340-1349. doi:10.1016/j.joca.2016.03.001
  - 44. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd Editio. (Hillsdale NJ. LE, ed.).; 1998.
  - 45. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower ex. *Arthritis Rheum*. 2001;45(4):384-391. doi:10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0

1 2		
3 4 5	46.	Roos EM, Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation and comparison to the WOMAC in total knee replacement. <i>Health Qual Life Outcomes</i> . 2003;1:17. doi:10.1186/1477-7525-1-17
6 7 8 9	47.	Dobson F, Bennell KL, Hinman RS, Abbott JH, Roos EM. Recommended performance - based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. <i>OARSI - Osteoarthr Res Soc Int</i> . 2013:1-26. doi:10.1016/j.joca.2013.05.002
10 11 12	48.	Dobson F, Hinman RS, Roos EM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. <i>Osteoarthr</i>
13 14 15		Curtu. 2013,21(8).1042-1052. doi:10.1010/j.joca.2015.05.002
16 17 18		
19 20 21		
22 23		
24 25 26		
27 28 29		
30 31 32		
33 34 35		
36 37 38		
39 40 41		
42 43 44		
45 46		
47 48 49		
50 51 52		
53 54 55		
56 57		
58 59		1



to beet terier only

## Table 1. Detailed timeline of the measurements to be taken at each point on the trials


	TIMELINE	Enrolment	STE protocol training	Baseline assessment (A1)	Intervention	Post- intervention assessment (A2)	Follow-up assessment (A3)	Follow-up assessment (A4)
	A A	-2 weeks (-14 to -7 day)	-1 week (-7 to 0 day)	Day 0		8 weeks (±3 days)	20 weeks (±3 days)	32 weeks (±3 days)
Enrolment	Eligibility screen Informed consent	X X						
Interventions	Allocation STE			X	V			
	STE STE + cryotherapy				X X			
	STE + sham cryotherapy				X X			
	X-ray examination of both knees	X		v		V	V	V
Assessments	VAS WOMAC			XX		X X	X X	X X
	KOOS			X		X	X	X
	SF-36			X X		X	X	X
	Timed-up and Go Test			Χ		Χ	Χ	Χ
	30-Second Chair to Stand Test			Χ		X	Х	Х
	Stair Climb Test			X		X	X	X
	. ,			X		X	X	X
c	40m (4x10m) Fast Paced Walk Test th Therapeutic Exercises; VAS: Visu e; KOOS: Knee Injury and Osteoarth ent	C	-			X sities Osteoarthrit	X	
								2

## Table 2.

Description of the test	Scoring	Minimum clinically important difference
The scale is placed in front of the patient who is asked to rate their pain intensity in the prior week. <sup>41</sup>	The scale ranges from 0 (no pain) to 10 cm (maximum pain intensity).	A pain reduction of 1.75 cm is recommended in OA research. <sup>42</sup>
This self-report questionnaire assesses the problems experienced by people with lower limb OA in the prior 72 hours. It contains 24 questions in 3 domains: pain, stiffness and physical function.	Each question is scored from 0 to 4. The maximum score is 96. High scores indicate worse status.	An improvement of 12% from baseline is recommended in OA research. <sup>45</sup>
This self-report questionnaire assesses the problems experienced by people with lower limb OA in the prior week, by measuring quality of life and knee function. It contains 42 questions in 5 domains: pain; other symptoms; function in daily life; sports-related function and recreation; and knee-related quality of life.	The answers are standardised and scored from 0 to 4. The total score is 168. High scores indicate worse status.	A difference of 8 to 10 i the total score is recommended in OA research. <sup>46</sup>
The participant is positioned in front of the stairs and, at the therapist signal, he/she has to climb the indicated steps (we used the 12-step SCT) and descend promptly, being able to use the handrail as a security instrument. We used 20 cm steps height, a handrail stair in an illuminated environment, free of traffic or external distractions. Moreover, a pre-test was conducted to identify the need for safety measures.	The final score was calculated based on the time the participant took to perform the test and compared to the normative values available for the test.	A reduction of 5.5 seconds in the test is the recommended MCID in OA research <sup>47</sup>
Administered at a distance of 10 meters (marked by tapes), a cone is placed 2 meters before the start and 2 meters after the end of each marking. The participant is instructed to walk as quickly but as safely as possible the first 10 meters (from the start mark), to turn around in the cone and walk back the 10 meters again, successively until completing the distance of 40 meters.	Speed (m/s)	An increase of 0.2-0.3 meters per second in the test is the recommended MCID in OA research <sup>47</sup>
A chair with no arms is placed against a wall to prevent oscillations. Patients sit in the middle of the chair, with their back straight and feet resting on the floor in line with their shoulders. The participant is asked to rise from sitting to standing as many times as possible in 30 seconds.	Total number of repetitions within 30 seconds	An increase of 2 to 3 repetitions is recommended in OA research. <sup>48</sup>
itis		
	The scale is placed in front of the patient who is asked to rate their pain intensity in the prior week. <sup>41</sup> This self-report questionnaire assesses the problems experienced by people with lower limb OA in the prior 72 hours. It contains 24 questions in 3 domains: pain, stiffness and physical function. This self-report questionnaire assesses the problems experienced by people with lower limb OA in the prior week, by measuring quality of life and knee function. It contains 42 questions in 5 domains: pain; other symptoms; function in daily life; sports-related function and recreation; and knee-related quality of life. The participant is positioned in front of the stairs and, at the therapist signal, he/she has to climb the indicated steps (we used the 12-step SCT) and descend promptly, being able to use the handrail as a security instrument. We used 20 cm steps height, a handrail stair in an illuminated environment, free of traffic or external distractions. Moreover, a pre-test was conducted to identify the need for safety measures. Administered at a distance of 10 meters (marked by tapes), a cone is placed 2 meters before the start and 2 meters after the end of each marking. The participant is instructed to walk as quickly but as safely as possible the first 10 meters (from the start mark), to turn around in the cone and walk back the 10 meters again, successively until completing the distance of 40 meters. A chair with no arms is placed against a wall to prevent oscillations. Patients sit in the middle of the chair, with their back straight and feet resting on the floor in line with their shoulders. The participant is asked to rise from sitting to standing as many times as possible in 30 seconds.	<ul> <li>The scale is placed in front of the patient who is asked to rate their pain intensity in the prior week.<sup>41</sup></li> <li>This self-report questionnaire assesses the problems experienced by people with lower limb OA in the prior 72 hours. It contains 24 questions in 3 domains: pain, stiffness and physical function.</li> <li>This self-report questionnaire assesses the problems experienced by people with lower limb OA in the prior week, by measuring quality of life and knee function. It contains 42 questions in 5 domains: pain, stiffness and physical function in daily life; sports-related function and recreation; and knee-related quality of life.</li> <li>The participant is positioned in front of the stairs and, at the therapist signal, he/she has to climb the indicated steps (we used the 12-step SCT) and descend promptly, being able to use the handrail as a security instrument. We used 20 cm steps height, a handrail stair in an illuminated environment, free of traffic or external distractions. Moreover, a pre-test was conducted to identify the need for safety measures.</li> <li>Administered at a distance of 10 meters (marked by tapes), a cone is placed 2 meters before the start and 2 meters after the end of each marking. The participant took to tur around in the come and walk back the 10 meters again, successively until completing the distance of 4.</li> <li>Achair with no arms is placed against a wall to prevent oscillations. Patients it in the matidel of the chair, with their back straight and feet resting on the floor in line with their shoulders. The participant tops server is a security in 30 seconds.</li> <li>The scale ranges from 0 is a seconds.</li> </ul>

#### Figure 1

Legend: Land Based Exercise Protocol Characteristics



Land Based Exercise Protocol Characteristics

107x139mm (300 x 300 DPI)

## **SUPPLEMENTARY FILE**

## Land-Based Exercises Protocol for Patients with Knee Osteoarthritis

## Warm-up Phase (10 min)







Description: treadmill, stationary bicycle, or walking. Performed in a comfortable cardiorespiratory intensity aiming the joints mobility.

## Cool-down Phase (10 min)



**Description: Quadriceps stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds



**Description: Gastrocnemius stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds





**Description: Hamstrings stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds

## **SUPPLEMENTARY FILE**

## **Conditioning PHASE 1**

57

58 59

60



Α



















## Name: Bridge

**Type: isometric Position A:** lie down on the mat, knees pointing to the ceiling, knees aligned with hips.

**Position B:** raise your hips up toward the ceiling and hold for 15 up to 30 s. **Sets:** 3 x 15-30 seconds

## Name: Straight Leg Raise (SLR) – hip flexion

## Type: Isotonic

**Position A:** lie down, one leg bent and another straight, pull up your foot. **Position B:** raise your leg straight up until it is aligned with the other thigh, then slowly lower it down. **Sets:** 3

Repetitions: 12

Name: SLR – hip abduction Type: Isotonic Position A: side lying position, bend the knee in contact with the floor and straight the other leg. Position B: raise your leg straight up, kneecap pointing forward, pulling up your foot. Sets: 3

Repetitions: 12

Name: SLR – hip adduction Type: Isotonic Position A: side lying position, leg in contact with the floor straight and the other leg bent. Position B: raise your leg straight up, kneecap pointing forward, pulling up your foot. Sets: 3

Repetitions: 12

Name: SLR – hip extension Type: Isotonic Position A: prone position, both legs straight touching the floor. Position B: raise one leg up at a time, keeping the totally knee straight. Sets: 3 Repetitions: 12

## **SUPPLEMENTARY FILE**

В

22

23

24 25

26

27

28

29

37 38 39

40 41 42

43

44

45

46

47

48

49

50 51 52

53

54 55

56

57

58

59

60



Α







## Name: Abdominal curls (crunchs) Type: Isotonic

**Position A:** lie down on the mat, place your hands behind your head, bend your knees and keep them aligned with hips.

**Position B:** as you exhale, slowly lift your chest up; as you inhale, slowly lower your chest down. Avoid bringing your chin to your chest. **Sets:** 3

Repetitions: 12

Name: Standing calf raises Type: Isotonic Position A: Standing on both legs, hands on the wall for balance (if needed). Position B: rise up on toes then slowly lower down. Sets: 3 Repetitions: 12

## **Conditioning PHASE 2**

В

Α







Name: Plank Type: Isometric Position A: lying on your belly (prone position). Position B: lift your entire body up with elbow and feet supports. Hold for 15 up to 30 seconds. Sets: 3 x 15-30 seconds

## Name: Bridge with one leg Type: Isometric

**Position A:** lie down on the mat, knees pointing to the ceiling, knees aligned with hips.

**Position B:** raise your hips up toward the ceiling then carefully take one leg off the floor. Hold for 15 up to 30 s. **Sets:** 3 x 15-30 seconds

## **SUPPLEMENTARY FILE**

В

60



Α











Name: Clam shell Type: Isotonic Position A: side lying position, elastic band around your thighs, knees bent. Position B: move your knee away, squeezing your buttocks then slowly return. Repeat with the other side/leg. Sets: 3 Repetitions: 12

## Name: Abdominal curls with lifted legs

## Type: Isotonic

Position A: lie down on the mat, place your hands behind your head, bend your knees and keep them aligned with hips. Lift both legs up.
Position B: as you exhale, slowly lift your chest up; as you inhale, slowly lower your chest down. Avoid bringing your chin to your chest.
Sets: 3

Repetitions: 12

## Name: Trunk extension Type: Isometric Position A: lying on your belly (prone position). Position B: move your chest away from the floor. Look at the ground. Hold for 30 seconds at least. Repetitions: 3 x 30 seconds

## Name: Wall squat

Type: Isometric contraction Position A: stand with your trunk to a wall, feet aligned with knees and hips, and away from the wall. Position B: slide down and keep your trunk towards the wall. Hold for 30 seconds up to one minute. Repetitions: 3

## Name: Partial squat Type: isotonic contraction Position A: standing on both legs. Position B: slowly bend your knees and stand up again. Maintain your knees over your feet. Repetitions: 3







## **SUPPLEMENTARY FILE**



Α



В













Name: Standing hip abduction. Type: static balance Position A: standing on both legs with an elastic band around both legs. Position B: lift one leg out, maintain the kneecap pointing forward, and hold for 30 seconds or more. Repetitions: 3 (each leg)

Name: Standing on one leg Type: static balance on stable surface Position A: standing on both legs, eyes opened.

**Position B:** standing on one leg, knee slightly bent, lift the other leg off the floor and maintain the position up to 1 minute.

Repetitions: 2 (each leg)

Name: Standing on one leg Type: static balance on unstable surface (trampoline, foam etc) Position A: standing on both legs, eyes opened. Position B: standing on one leg,

remove another leg from ground and maintain the position. **Repetitions:** 2 (each leg)

#### Name: Step-up

Type: isotonic contraction Position A: on leg onto a step. Position B: step up onto the next step, use the wall for balance if needed. Step back down carefully to the position A. Sets: 2 (each leg) Repetitions: 12

 BMJ Open



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	ltem No	Description
Administrative in	format	ion
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym – <b>PAGE 01</b>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry <mark>– PAGE 02</mark>
	2b	All items from the World Health Organization Trial Registration Data Set - N/A
Protocol version	3	Date and version identifier - N/A
Funding	4	Sources and types of financial, material, and other support - PAGE 14
Roles and	5a	Names, affiliations, and roles of protocol contributors – PAGE 01
responsibilities	5b	Name and contact information for the trial sponsor - N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities - N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) - N/A
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention – PAGE 4-6
	6b	Explanation for choice of comparators – PAGE 4-6
Objectives	7	Specific objectives or hypotheses – PAGE 4-6

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg superiority, equivalence, noninferiority, exploratory) – PAGE 6
Methods: Partici	pants,	interventions, and outcomes
Study setting	9	Description of study settings (eg, community clinic, academic hospita and list of countries where data will be collected. Reference to where list of study sites can be obtained – PAGE 6
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibilit criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) – PAGE 7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered <mark>– PAGE 8-10</mark>
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) – PAGE 8-10
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) – PAGE 8-10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial <mark>– PAGE 8-10</mark>
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended – PAGE 11
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) – PAGE 21
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations – PAGE 12
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size <mark>– PAGE 7</mark>
Methods: Assigr	nment	of interventions (for controlled trials)
Allocation:		

_			
1 2 3 4 5 6 7 8 9	Sequence generation	16a	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions – PAGE 11,12
10 11 12 13 14	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned <b>– PAGE 11,12</b>
15 16 17	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions – PAGE 11,12
18 19 20 21 22	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how <b>– PAGE 8, 9, 11, 12</b>
23 24 25 26		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial <b>– PAGE 8, 9, 11, 12</b>
27 28	Methods: Data co	llectio	on, management, and analysis
29 30 31 32 33 34 35 36 37	Data collection Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol <b>– PAGE 12, 13</b>
37 38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols <b>– PAGE 12, 13</b>
42 43 44 45 46 47 48	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol – PAGE 12, 13
49 50 51 52	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol – PAGE 12, 13
53 54 55 56		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses) <mark>– PAGE 12, 13</mark>
50 57 58 59 60		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) – PAGE 12, 13

1 2 3 4 5	
6 7 8 9 10 11 12	
13 14 15 16 17 18	
19 20 21 22 23 24 25	
23 26 27 28 29 30 31	
32 33 34 35 36 37	
38 39 40 41 42 43	
44 45 46 47 48 49	
50 51 52 53 54 55 56	
57 58 59 60	

Methods: Monitor	ina	
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed <b>N/A</b>
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial <b>– PAGE 5-7</b>
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct – PAGE 5-7
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor – PAGE 5-7
Ethics and dissen	ninatio	n
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval <mark>– PAGE 13, 14</mark>
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) – PAGE 13, 14
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) – PAGE 13, 14
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial <b>– PAGE 06, 07</b>
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site <mark>– PAGE 1</mark> 4
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators <b>N/A</b>
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation N/A

2 3 4 5	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other
6 7 8			data sharing arrangements), including any publication restrictions <mark>–</mark> PAGE 13, 14
9 10 11		31b	Authorship eligibility guidelines and any intended use of professional writers N/A
11 12 13 14		31c	Plans, if any, for granting public access to the full protocol, participant- level dataset, and statistical code – PAGE 13, 14
15 16	Appendices		
17 18 19	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates <b>N/A</b>
20 21 22 23 24	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable <b>N/A</b>
24 25	*It is strongly recor	nmenc	led that this checklist be read in conjunction with the SPIRIT 2013


It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.

# **BMJ Open**

## CRYOTHERAPY ASSOCIATED WITH TAILORED LAND-BASED EXERCISES FOR KNEE OSTEOARTHRITIS: A PROTOCOL FOR A RANDOMIZED TRIAL

1	RM1 Onen
Journal:	BMJ Open
Manuscript ID	bmjopen-2019-035610.R1
Article Type:	Protocol
Date Submitted by the Author:	17-Feb-2020
Complete List of Authors:	Ogura Dantas, Lucas; Federal University of Sao Carlos, Physiotherapy Serafim Jorge, Ana Elisa; Federal University of Sao Carlos, Physiotherapy Serrao, Paula; Federal University of Sao Carlos, Physiotherapy Sendín, Francisco; Universidad de Córdoba, 2Sociosanitary Sciences, Radiology and Physical Medicine, University of Córdoba, Córdoba, Spain and Instituto Maiomónides de Investigación Biomédica de Córdoba (IMIBIC) Salvini, Tania; Federal University of Sao Carlos, Physiotherapy
<b>Primary Subject Heading</b> :	Rheumatology
Secondary Subject Heading:	Rheumatology, Rehabilitation medicine
Keywords:	PAIN MANAGEMENT, REHABILITATION MEDICINE, PUBLIC HEALTH

SCHOLARONE<sup>™</sup> Manuscripts BMJ



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2 3	1
4 5	
6	2
7 8 9	3
10 11	4
12 13	5
14 15	6
16 17 19	7
18 19 20	8
21 22	9
23 24	10
25 26	11
27 28 29	12
30 31	13
32 33	14
34 35	
36 37	15
38 39	16
40 41	17
42 43 44	18
44 45 46	19
47 48	20
49 50	21
51 52	21
53 54	
55 56	
57 58	
59 60	

TITLE: CRYOTHERAPY ASSOCIATED WITH TAILORED LAND-BASED EXERCISES FOR KNEE OSTEOARTHRITIS: A PROTOCOL FOR A RANDOMIZED TRIAL Lucas Ogura Dantas<sup>1</sup>, PT; Ana Elisa Serafim Jorge<sup>1</sup>, PT, MSc, PhD; Paula Regina Mendes Silva Serrao<sup>1</sup>, PT, MSc, PhD; Francisco Alburguergue-Sendín<sup>2</sup>, PT, MSc, PhD; Tania Fatima Salvini<sup>1</sup>,

PT, MSc, PhD.

Author Affiliations: <sup>1</sup>Physical Therapy Department, Federal University of São Carlos, São Carlos, Brazil. <sup>2</sup>Sociosanitary Sciences, Radiology and Physical Medicine, University of Córdoba, Córdoba, Spain and Instituto Maiomónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.

Corresponding Author: Tania Fatima Salvini, PT, MSc, PhD. Neuromuscular Plasticity Laboratory, Physical Therapy Department, Federal University of São Carlos, Rodovia Washington Luiz, Km 235, CEP:13.565-905, CxP: 676, São Carlos, SP, Brazil (tania@ufscar.br)

#### BMJ Open

### 1 ABSTRACT

**Introduction:** There is an unmet need to develop tailored therapeutic exercise protocols applying different treatment parameters and modalities for individuals with knee osteoarthritis (KOA). Cryotherapy is widely used in rehabilitation as an adjunct treatment due to its effects on pain and the inflammatory process. However, disagreement between KOA guidelines remains with respect to its recommendation status. The aim of this study is to verify the complementary effects of cryotherapy when associated with a tailored therapeutic exercise protocol on patients with KOA. Methods and analysis: This study is a placebo-controlled, randomized trial with concealed allocation and intention-to-treat analysis. Assessments will be performed at baseline and immediately following the intervention period. To check for residual effects of the interventions applied, three- and six-month follow-up assessments will be performed. Participants will be community members living with KOA. There will be three groups: (1) the experimental group that will receive a tailored therapeutic exercise protocol followed by a cryotherapy session of 20 minutes; (2) the sham control group that will receive the same regimen as the first group, but with sham packs filled with dry sand; and (3) the active treatment control group that will receive only the therapeutic exercise protocol. The primary outcome will be pain intensity according to a Visual Analogue Scale. Secondary outcomes will be the Western Ontario & McMaster Universities Osteoarthritis Index; the Medical Outcomes Survey Short-Form 36 questionnaire; the 30-Second Chair Stand Test; the Stair Climb test; and the 40-Meter fast-paced walk test.

20 Ethics and dissemination: The trial was approved by the Institutional Ethics Committee of
21 Federal University of Sao Carlos, São Paulo, Brazil. Registration approval number: CAAE:
22 65966617.9.0000.5504. The results will be published in peer-reviewed journals.

#### 23 Trial registration number: NCT03360500

2 3	1	Strengths and limitations of this study:
4 5		
6 7	2	<ul> <li>The trial will be conducted according to well-established reporting guidelines.</li> </ul>
, 8 9	3	<ul> <li>Participants will present with radiographically confirmed knee osteoarthritis and a</li> </ul>
10 11	4	sufficient level of pain to ensure ample scope for improvement.
12 13	5	<ul> <li>The trial will use both subjective and objective outcome measures.</li> </ul>
14 15	6	• The therapist who delivers cryotherapy or the placebo intervention and the patients will not
16 17	7	be blinded.
18 19 20	8	<ul> <li>The loss to follow-up after randomization in the placebo group might be higher than those</li> </ul>
20 21 22	9	in the other groups.
23 24	10	
25 26	11	
27 28	12	The loss to follow-up after randomization in the placebo group might be higher than those in the other groups.
29 30 31	12	
31 32 33		
34 35	14	
36 37	15	
38 39	16	
40 41 42	17	
42 43 44		
45 46		
47 48		
49 50		
51 52		
53 54		
55 56		
57 58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

Knee osteoarthritis (KOA) is a serious disease with a high societal and economic burden,<sup>1</sup> affecting approximately 250 million people worldwide.<sup>2</sup> Current clinical practice guidelines recommend a combination of pharmacological<sup>3</sup> and non-pharmacological<sup>4</sup> treatment strategies to manage KOA symptoms and improve patients' quality of life. However, pharmacological treatment options that have been proven to relieve symptoms remain limited, and some of the most commonly recommended pharmacologic treatments are poorly tolerated, with long-term use resulting in serious systemic adverse events.<sup>5–7</sup>

Physical Therapy, specifically the use of strengthening therapeutic exercise (STE) protocols, have been shown to relieve pain, reduce stiffness, increase physical function, and improve quality of life in patients with KOA.<sup>1,8</sup> High-quality evidence has demonstrated that the benefits of STE protocols on pain and quality of life in individuals with KOA are sustained for at least two to six months after the end of a treatment.<sup>8</sup> There is, however, a call for further research to develop novel insights within STE protocols regarding differences in treatment durations, frequencies, modalities, and intensities.<sup>9</sup> The majority of current protocols have reported low adherence and are substantially under-utilized by KOA patients, mainly due to socioeconomic barriers, personal beliefs, fear of movement, and aggravation of pain in the early phases of treatment.<sup>10,11</sup> Therefore, there is an unmet need for cost-effective, evidence-based STE protocols that are tailored to the needs of KOA patients, and that can aid clinicians in targeting rehabilitation goals.

Physical modalities such as thermal agents, laser therapy, therapeutic ultrasound, and electrical
 stimulation are often used as adjunct treatments with therapeutic exercises in individuals with
 KOA.<sup>4,12</sup> Cryotherapy, a non-pharmacological intervention, has been widely used in some

rheumatic joint diseases<sup>13,14</sup> based on its effects on pain, inflammation, and edema.<sup>15,16</sup> The intervention is considered safe, and is inexpensive and easy to administer for healthcare professionals and patients. Moreover, it can be prescribed in isolation or as an adjunct treatment and seems to be well accepted by individuals with KOA.<sup>14,17,18</sup> Although cryotherapy is recommended as a treatment option by some international KOA guidelines,<sup>19,20</sup> others have found insufficient evidence to support it.<sup>21–23</sup> Relevant systematic reviews have likewise concluded that further evidence, produced with greater methodological rigor, is needed to evaluate the effects of cryotherapy on pain, function, and quality of life in individuals with KOA.<sup>16,24</sup> 

In this study, we aim to design a randomized trial to verify the complementary effects of cryotherapy in conjunction with a tailored STE protocol on pain, function, and quality of life in individuals with KOA. We hypothesize that cryotherapy combined with the STE protocol will achieve better treatment effects on KOA patients when compared to the other two groups. The proposed trial will contribute new evidence to the Physical Therapy field in KOA by focusing on interventions that target rehabilitation and enhance pain management, thereby improving the physical function and quality of life of these patients. Our research group developed the STE protocol described in this study. The protocol was also used in another randomized trial testing the complementary effects of Photobiomodulation in individuals with KOA (trial registration number at www.ensaiosclinicos.gov.br: U1111-1215-6510). This manuscript has been submitted simultaneously with the manuscript entitled "Photobiomodulation therapy associated with supervised therapeutic exercises for people with knee osteoarthritis: a protocol for randomized trials" (ID bmjopen-2019-035711).

#### **BMJ** Open

#### 1 METHODS

To report this study protocol, we followed the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT),<sup>25</sup> the Osteoarthritis Research Society International clinical trials recommendations: design, conduct, and reporting of clinical trials for knee osteoarthritis,<sup>26</sup> and the Template for Intervention Description and Replication checklist (TIDieR).<sup>27</sup> The randomized trial will be reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement for randomized trials of non-pharmacologic treatments.<sup>28</sup> The trial is registered on the clinicaltrials.gov (NCT03360500) platform.

#### 10 Study design and setting

This study is a single-center, placebo-controlled randomized clinical trial. A baseline assessment (A1) will be performed on the weekday before the 8-week intervention period, and a postintervention assessment (A2) will be performed immediately following the last session. To check for residual effects of the interventions, three-month (A3) and six-month (A4) follow-up assessments will be performed. Each patient will be assessed in a physiotherapy research laboratory, during the same period of the day and by the same assessor. To reduce bias, the therapists responsible for applying the intervention and the outcome assessors will follow standardized scripts that describe the general objective of the study.<sup>26</sup> 

Intervention adherence, medication intake, and adverse events will be tracked with an 8-week assessment diary that will be given to participants at the baseline assessment and with a 12-week assessment diary for the three-month follow-up assessment. All the participants will be advised not to practice any other type of regular physical exercise during the course of the study that could

interfere with the STE protocol. A verbal and written explanation of the objectives and methodology of the study will be provided to all the participants, and those willing to participate will sign a written informed consent form, approved by the local ethics committee. A detailed timeline of the trial is presented in **Table 1**.

#### 6 Patient and Public Involvement

The patients and the public were not involved in the planning and design of this study.

#### **Participants**

Participants will be recruited through public announcements on social media, advertisements via local news outlets, University community newsletters, and banners or leaflets posted at strategic locations in the city. People who are interested in participating in the study will first be screened to check the eligibility criteria. Eligible participants will then undergo a lateral, anteroposterior, and axial radiography of both knees to determine KOA severity, which will take place at the University Hospital. Participants will be classified with KOA based on the clinical and radiographic criteria of the American College of Rheumatology,<sup>29</sup> and will be required to have symptoms and a radiographic grade (Kellgren and Lawrence scale) of  $\geq 2$  (mild radiographic OA) in at least one knee compartment.<sup>26</sup> 

To be included in the study, participants will also need to: be between 40 and 75 years old; be engaged in a total of less than 45 minutes/week of physical activity of at least moderate intensity<sup>30</sup>; have a body mass index  $<35 \text{ kg/m}^2$ ; and to have reported pain intensity in the prior week of  $\geq$ 4 cm on a 10-cm visual analogue scale.<sup>26</sup> Exclusion criteria will comprise physical therapy in the prior

#### **BMJ** Open

three months; intra-articular knee injections in the prior six months; medical restrictions such as cardiorespiratory, neurological, or any other rheumatology conditions; previous hip, knee, or ankle surgery; and any other chronic condition that leads to chronic pain or dysfunction. Additionally, participants presenting with contraindication(s) to cryotherapy application (i.e., those that feel a high level of discomfort or pain during the application) will be excluded.

All the participants will be asked to provide a medical certificate stating that they are healthyenough to perform physical activities before the start of the intervention.

9 Interventions

Two physical therapists will administer the interventions in the physiotherapy clinic of the University. The study will take place over the course of eight weeks, with three 90-minute sessions per week occurring on non-consecutive days, for a total of 24 sessions. All randomized participants will perform the STE protocol and then, according to random allocation, each patient will subsequently receive either cryotherapy or sham interventions in individual rooms.

Prior to the beginning of the study, the therapists responsible for the interventions will participate in a 10-hour training module, which will consist of scientific information and clinical training regarding KOA, the STE protocol, and the use of cryotherapy. After the first training module is completed, the therapists will do an eight-week training module, which will consist of practicing the full-length protocol and intervention application(s) three times per week. Both therapists will be responsible for delivering cryotherapy and sham interventions.

#### 1 <u>STE protocol</u>

We designed the 8-week land-based supervised exercise protocol according to the evidence-based recommendations for physical exercise interventions in KOA.<sup>31,32</sup> The STE protocol characteristics are described in Figure 1, and a detailed description of all the exercises is presented in the **Supplementary file** of this protocol. The protocol is divided into two phases. Each phase consists of 4 weeks of progressive exercises, performed three times per week on non-consecutive days (24 hours rest between sessions), with exercise intensity individually tailored for each participant. The first session is used to demonstrate and explain the STE protocol, and to perform an exercise familiarization using no loads by the participants. The second session is designed to estimate the initial resistance of each participant for each exercise. The volitional interruption method is used in order to achieve the benefits of resistance training and to reduce the risk of musculoskeletal injuries to the participants.<sup>33</sup> The loads are gradually increased until the participant can adequately perform 12 repetitions with no voluntary interruption due to muscle fatigue.

The STE protocol sessions consist of three phases. The first phase is a 10-minute warm-up in which the patients can choose, according to their preferences, to walk in a comfortable intensity in an outdoor circuit, treadmill, or ride in a stationary bicycle. The second phase consists of 40 minutes of strengthening exercises (resistance training), such as a lower limb and trunk muscles, and neuromuscular training involving balance exercises. The third phase is a cool-down phase, consisting of static stretching exercises to reduce the risk of musculoskeletal injuries and to maximize the benefit of the STE protocol.<sup>34</sup> Cardiac and respiratory frequencies and blood pressure are monitored at the beginning of each session or if the participant presents an intense

#### **BMJ** Open

rate of perceived exertion according to the Borg scale while performing an exercise, to ensure
 patient safety.<sup>35,36</sup>

#### 4 Cryotherapy protocol

To apply cryotherapy, the therapist will explain to the patient that the intervention will consist of crushed ice applied to the more-affected knee for 20 minutes. Participants will be positioned in dorsal decubitus with both legs extended and relaxed. The entire knee surface will be covered with a moist surgical gauze ( $45 \times 50 \times 0.01$  cm) to protect the skin from possible frostbite. Next, two plastic bags  $(24 \times 34 \times 0.08 \text{ cm})$ , each containing 1 kg of crushed ice, will be placed on the knee, covering the anterior, posterior, medial, and lateral surfaces. A comfortable, non-painful compression will be applied over the ice packs by wrapping an elastic bandage around them, and the therapy will be left in situ, uninterrupted, for 20 minutes. The primary purpose of compression is to maintain the ice packs in position on the knee<sup>37</sup> and to enhance cryotherapy effects.<sup>38</sup> 

For the sham cryotherapy intervention, the bags will be filled with 1 kg of dry sand instead of ice. The sandbags will be applied according to the same regimen in the same locations. The therapist's explanation about the intervention will be changed to mention the 'application of sand packs' instead of 'cryotherapy application.' The sandbags will be applied with the same gauze underneath and the same bandage for compression.

#### **Outcome measures**

The same blinded assessor will measure all outcomes before and after the intervention, and at the 3- and 6-month follow-up periods. Before the study begins, the two outcome assessors will be

trained to conduct interviews and perform data collection following a standard protocol. **Table 2** describes the outcome measures that will be included in the trial and the recommended estimate of the minimum clinically important difference (MCID) for each outcome measure. We will measure pain intensity, subjective and objective physical function, and quality of life.

*Primary outcome* 

7 The primary outcome will be pain intensity at rest, assessed with a Visual Analogue Scale (VAS).
8 This self-reported pain score is a valid and reliable measure for KOA.<sup>39</sup> The VAS will be
9 administered at rest and after each physical function test, occurring at baseline, on the final
10 assessment day, and at the 3- and 6-month follow-up periods.

#### 12 Secondary outcomes

To subjectively assess physical function and associated problems, the Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) will be used. WOMAC is a frequently used questionnaire in KOA and is translated, reproducible, and valid to Brazilian Portuguese.<sup>40</sup> The Medical Outcomes Survey Short-Form 36 (SF-36) questionnaire will be used to asses quality of life. The questionnaire is translated, reproducible, and valid to use in Brazilian Portuguese.<sup>41</sup> Three objective physical function tests will also be used: The 30-Second Chair Stand test, the Stair Climb test, and the 40-Meter fast-paced walk test. The questionnaires and physical function tests described are well-established core assessment measures of pain and physical function in patients with KOA, and presenting good scores for reliability, validity, and ability to detect change.<sup>42–46</sup> 

#### BMJ Open

#### 1 Randomization

Eligible patients who consent to participate will be randomly allocated into three groups of 40: (1) active control group that will receive the STE protocol only, (2) STE + cryotherapy group, and (3) STE + sham cryotherapy group. The allocation of patients will be performed using permuted block randomization stratified by gender (20 men and 20 women in each group); randomization sequences will be determined by a computer-generated random numbers program (www.randomization.com). Allocation will be concealed by placing randomization assignments in opaque sealed envelopes that will be locked in a central location. A biostatistician will be responsible for generating the random numbers and each participant's random allocation will be revealed to the therapist administering the intervention just before study onset.<sup>26</sup> 

#### 

#### 12 Sample size

We aim to detect a minimum clinically important difference (MCID) of 1.75 cm units on the VAS for pain intensity at rest.<sup>47</sup> Also, we aim to detect an MCID of 30 points on the WOMAC global score.<sup>48</sup> Calculations were based on an analysis of covariance adjusting for baseline outcome scores, assuming between-patient standard deviations of 2.0 cm for pain and 45 points for WOMAC global score. Based on these criteria, to achieve a significance level of 0.05 and a power of 0.80%, 37 participants with KOA will be required in each group. We will recruit 40 participants per group to allow possible dropouts during the intervention period.

#### 21 Data analysis

The analyses will be performed by a blinded biostatistician using commercial software. The
Kolmogorov-Smirnov test will be applied to evaluate the normality of data distribution. If the

distribution is not normal, non-parametric tests will be used. For normal distributions, a 2-factor analysis of variance (ANOVA) will be conducted for the primary outcome (visual analogue scale for pain) and secondary outcomes, with time (baseline, post-intervention, and follow-up) as the within-subject factor and group (STE, STE + cryotherapy, STE + sham cryotherapy) as the between-subject factor. In addition, Tukey's test will be used for post-hoc analysis when necessary, and an intention-to-treat analysis will be performed for all randomized participants. All the missing data will be replaced using the expectation-maximization method. Between-group differences and their 95% confidence intervals will be reported and interpreted against the nominated thresholds for MCID. For the outcomes where the MCID is not nominated, Cohen's *d* coefficient will be calculated to aid interpretation. An effect size greater than 0.8 will be considered large, around 0.5 moderate, and less than or equal to 0.2, small<sup>49</sup>.

#### 13 ETHICS AND DISSEMINATION

The Institutional Ethics Committee of the Federal University of Sao Carlos, São Paulo, Brazil, approved the under the registration approval number: CAAE: 65966617.9.0000.5504. The trial will be conducted according to the Helsinki Statement. All participants will provide written informed consent following a verbal and written explanation of the study protocol. Participants will be free to withdraw from the trial at any time without prejudice to future treatment. Results will be presented at scientific meetings and published in peer-reviewed journals. All publications and presentations related to the study will be authorized and reviewed by the study investigators.

BMJ Open

2		
3	1	TRIAL STATUS
4 5		
6 7	2	The trial is currently recruiting and is expected to be completed (including follow-up testing) by
, 8 9	3	December 2020.
) 10 11	4	
12 13	5	AUTHORS CONTRIBUTION
14 15 16	6	L.O.D., A.E.S.J., P.R.S., F.A.S., and T.F.S. designed the study protocol. L.O.D. wrote the first
16 17 18	7	draft of the manuscript, and together with A.E.S.J., P.R.S., F.A.S., and T.F.S. revised and produced
19 20	8	the final version. All authors have read and approved the final version of the manuscript. L.O.D.
21 22	9	takes responsibility for the integrity of the work as a whole.
23 24	10	
25 26 27	11	FUNDING
28 29	12	LOD and AESJ were financially supported by Sao Paulo Research Foundation (FAPESP, Process
30 31 32	13	numbers #2018/23705-3, and #2017/00062-7 respectively) and Conselho Nacional de
33 34	14	Desenvolvimento Científico e Tecnológico (CNPQ # 401333/2016-7).
35 36	15	
37 38 39	16	DISCLAIMER
40 41	17	The study funders have had no role in study design; collection, management, analysis and
42 43	18	interpretation of data; writing of the report; or the decision to submit the report for publication,
44 45 46	19	and do not own ultimate authority over any of these activities.
46 47 48	20	
49 50	21	COMPETING INTERESTS
51 52 53 54 55 56 57 58	22	All authors have completed a uniform disclosure form and declare no conflicts of interest
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### REFRENCES

Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet (London, England)*.
 2019;393(10182):1745-1759. doi:10.1016/S0140-6736(19)30417-9

 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2163-2196. doi:10.1016/S0140-6736(12)61729-2

- Mandl LA. Osteoarthritis year in review 2018: clinical. *Osteoarthr Cartil.* 2018;(xxxx):1 6. doi:10.1016/j.joca.2018.11.001
- 4. Collins NJ, Hart HF, Mills KAG. OARSI year in review 2018: rehabilitation and outcomes. *Osteoarthr Cartil*. 2018;0(0). doi:10.1016/j.joca.2018.11.010
- Vowles KE, Mcentee ML, Siyahhan P, Frohe T, Ney JP, Goes DN Van Der. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain.* 2015;156(4). http://www.nejm.org/doi/10.1056/NEJMra1507771.
- Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain Misconceptions and Mitigation Strategies. N Engl J Med. 2016;374(13):1253-1263. doi:10.1056/NEJMra1507771
- Deveza LA, Hunter DJ, Van Spil WE. Too much opioid, too much harm. Osteoarthr Cartil. 2018;26(3):293-295. doi:10.1016/j.joca.2017.12.003
- Fransen M, Mcconnell S, Ar H, M VDE, Simic M, Kl B. Exercise for osteoarthritis of the knee. *Cochrane Libr*. 2015;(1):1-144. doi:10.1002/14651858.CD004376.pub3.www.cochranelibrary.com
- 9. Lee AC, Harvey WF, Price LL, et al. Dose-Response Effects of Tai Chi and Physical Therapy Exercise Interventions in Symptomatic Knee Osteoarthritis. *PM&R*.
  - 2018;10(7):712-723. doi:10.1016/j.pmrj.2018.01.003
- Nicolson PJAA, Bennell KL, Dobson FL, Van Ginckel A, Holden MA, Hinman RS. Interventions to increase adherence to therapeutic exercise in older adults with low back pain and/or hip/knee osteoarthritis: a systematic review and meta-analysis. *Br J Sports Med.* 2017;51(10):791-799. doi:10.1136/bjsports-2016-096458
- Dobson F, Bennell KL, French SD, et al. Barriers and Facilitators to Exercise Participation in People with Hip and/or Knee Osteoarthritis. *Am J Phys Med Rehabil*.

60

#### BMJ Open

1 2		
3		2016;95(5):1. doi:10.1097/phm.00000000000448
4 5	12.	Oo WM, Thae Bo M. Efficacy of Physical Modalities in Knee Osteoarthritis: Recent
6 7		Recommendations. Int J Phys Med Rehabil. 2016;04(03):3-4. doi:10.4172/2329-
8		9096.1000e112
9		
10 11	13.	Demoulin C, Vanderthommen M. Cryotherapy in rheumatic diseases. Jt Bone Spine.
12		2012;79(2):117-118. doi:10.1016/j.jbspin.2011.09.016
13 14	14.	Guillot X, Tordi N, Mourot L, et al. Cryotherapy in inflammatory rheumatic diseases: A
15		systematic review. Expert Rev Clin Immunol. 2014;10(2):281-294.
16 17		doi:10.1586/1744666X.2014.870036
18	1.5	
19 20	15.	Bleakley CM, Davison GW. Cryotherapy and inflammation: evidence beyond the cardinal
20		signs. Phys Ther Rev. 2010;15(6):430-435. doi:10.1179/1743288X10Y.0000000014
22 23	16.	Dantas LO, Moreira R de FC, Norde FM, Mendes Silva Serrao PR, Alburquerque-Sendín
23 24		F, Salvini TF. The effects of cryotherapy on pain and function in individuals with knee
25		osteoarthritis: a systematic review of randomized controlled trials. <i>Clin Rehabil</i> . April
26 27		
28		2019:026921551984040. doi:10.1177/0269215519840406
29 30	17.	Porcheret M, Jordan K, Jinks C. Primary care treatment of knee pain - A survey in older
31		adults. Rheumatology. 2007;46(11):1694-1700. doi:10.1093/rheumatology/kem232
32 33	18.	Denegar CR, Dougherty DR, Friedman JE, et al. Preferences for heat, cold, or contrast in
34		patients with knee osteoarthritis affect treatment response. Clin Interv Aging. 2010;5:199-
35 36		206. doi:10.2147/CIA.S11431
37	10	
38 39	19.	Chae KJ, Choi MJ, Kim KY, Ajayi FF, Chang IS, Kim IS. National Institute for Health
40		and Care Excellence. Osteoarthritis: Care and Management. December 2014.
41 42	20.	Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012
42 43		recommendations for the use of nonpharmacologic and pharmacologic therapies in
44		osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-474.
45 46		
47		doi:10.1002/acr.21596
48 49	21.	McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical
50		management of knee osteoarthritis. Osteoarthr Cartil. 2014;22(3):363-388.
51 52		doi:10.1016/j.joca.2014.01.003
53	22.	Fernandes L, Hagen KB, Bijlsma JWJJ, et al. EULAR recommendations for the non-
54 55		
56		pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis.
57 58		
58 59		16
<u> </u>		For peer review only - http://bmiopen.hmi.com/site/about/quidelines.yhtml

4

5

6

7 8

9 10

11

12 13

14 15

16 17

18

19 20

21 22

23

24 25

26 27

28 29

30

31 32

33 34

35 36

37

38 39

40 41

42

43 44

45 46

47 48

49

50 51

52 53

54 55

60

2013;72(7):1125-1135. doi:10.1136/annrheumdis-2012-202745 Brosseau L, Taki J, Desjardins B, et al. The Ottawa panel clinical practice guidelines for 23. the management of knee osteoarthritis. Part two: strengthening exercise programs. Clin Rehabil. 2017;31(5):596-611. doi:10.1177/0269215517691084 24. Brosseau L, Yonge K a, Robinson V, et al. Thermotherapy for treatment of osteoarthritis. Cochrane Database Syst Rev. 2003;(4):CD004522. doi:10.1016/S0031-9406(05)60490-7 25. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med. 2013;158(3):200. doi:10.7326/0003-4819-158-3-201302050-00583 26. McAlindon TE, Driban JB, Henrotin Y, et al. OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthr Cartil. 2015;23(5):747-760. doi:10.1016/j.joca.2015.03.005 27. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348(mar07 3):g1687. doi:10.1136/bmj.g1687 28. Barbour V, Bhui K, Chescheir N, et al. CONSORT Statement for randomized Trials of nonpharmacologic treatments: A 2017 update and a CONSORT extension for nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. doi:10.7326/M17-0046 29. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039-1049. doi:10.1002/art.1780290816 30. Dunlop DD, Song J, Lee J, et al. Physical Activity Minimum Threshold Predicting Improved Function in Adults With Lower-Extremity Symptoms. Arthritis Care Res. 2017;69(4):475-483. doi:10.1002/acr.23181 31. Messier SP, Mihalko SL, Beavers DP, et al. Strength training for arthritis trial (START): Design and rationale. BMC Musculoskelet Disord. 2013;14(1):1. doi:10.1186/1471-2474-14-208 32. Fransen M, McConnell S, Harmer AR, Van Der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee: A Cochrane systematic review. Br J Sports Med.

#### **BMJ** Open

2		
3		2015;49(24):1554-1557. doi:10.1136/bjsports-2015-095424
4 5	33.	Nóbrega SR, Ugrinowitsch C, Pintanel L, Barcelos C, Libardi CA. Effect of Resistance
6 7		Training to Muscle Failure vs. Volitional Interruption at High- and Low-Intensities on
8		Muscle Mass and Strength. J Strength Cond Res. 2018;32(1):162-169.
9 10		doi:10.1519/JSC.00000000001787
11 12	34.	Bennell KL, Dobson F, Hinman RS. Exercise in osteoarthritis: Moving from prescription
13	54.	to adherence. <i>Best Pract Res Clin Rheumatol</i> . 2014;28(1):93-117.
14 15		
16	2.5	doi:10.1016/j.berh.2014.01.009
17 18	35.	American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription
19 20		for older adults with osteoarthritis pain: consensus practice recommendations. A
20 21		supplement to the AGS Clinical Practice Guidelines on the management of chronic pain in
22 23		older adults. Jags. 2001;49(6):808-823. doi:10.1046/j.1532-5415.2001.00496.x
24	36.	Vincent KR, Vincent HK. Resistance exercise for knee osteoarthritis. PM R. 2012;4(5
25 26		Suppl):S45-52. doi:10.1016/j.pmrj.2012.01.019
27	37.	Silva P, Lott R, Wickrama S, Mota J, Welk G. Elastic Bandaging for Orthopedic and
28 29		Sports Injuries Prevention and Rehabilitation: A Systematic Review. Int J Sport Nutr
30 31		<i>Exerc Metab.</i> 2016;32:1-44. doi:10.1123/ijspp.2015-0012
32	38.	Song M, Sun X, Tian X, et al. Compressive cryotherapy versus cryotherapy alone in
33 34	50.	patients undergoing knee surgery: a meta-analysis. <i>Springerplus</i> . 2016;5(1):1-12.
35 36		
37	20	doi:10.1186/s40064-016-2690-7
38 39	39.	Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog
40		Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain
41 42		Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain
43 44		Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. Arthritis Care Res
45		(Hoboken). 2011;63(S11):S240-S252. doi:10.1002/acr.20543
46 47	40.	MI F. Tradução e validação do questionário de qualidade de vida específico para
48		osteoartrose WOMAC (Western Ontario McMaster Universities) para a língua portuguesa.
49 50		2003.
51 52	41.	Ciconelli RM, Ferraz MB, Santos W, Meinao I, Quaresma MR. Brazilian-Portuguese
53		version of the SF-36. A reliable and valid quality of life outcome measure. <i>Rev Bras</i>
54 55		<i>Reumatol.</i> 1999;39(3):143-150.
56		100000000 1777,57(5).115 150.
57 58		
50		10

3 4	42.	Dobson F, Bennell KL, Hinman RS, Abbott JH, Roos EM. Recommended performance -
5		based tests to assess physical function in people diagnosed with hip or knee osteoarthritis.
6 7		OARSI - Osteoarthr Res Soc Int. 2013:1-26. doi:10.1016/j.joca.2013.05.002
8	43.	Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of
9 10		Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the
11 12		Hand, Hip, and Knee. Arthritis Rheumatol. 2020;0(November):art.41142.
13		doi:10.1002/art.41142
14 15		
16	44.	Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical
17 18		management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil.
19		2019;27(11):1578-1589. doi:10.1016/j.joca.2019.06.011
20 21	45.	Pham T, van der Heijde D, Altman R., et al. OMERACT-OARSI Initiative: Osteoarthritis
22		Research Society International set of responder criteria for osteoarthritis clinical trials
23 24		revisited. Osteoarthr Cartil. 2004;12(5):389-399. doi:10.1016/j.joca.2004.02.001
25	16	Bennell K, Dobson F, Hinman R. Measures of physical performance assessments: Self-
26 27	46.	
28		Paced Walk Test (SPWT), Stair Climb Test (SCT), Six-Minute Walk Test (6MWT), Chair
29		Stand Test (CST), Timed Up & amp; Go (TUG), Sock Test, Lift and Carry Test (LCT),
30 31		and Car Task. Arthritis Care Res (Hoboken). 2011;63(S11):S350-S370.
32 33		doi:10.1002/acr.20538
34	47.	Bellamy N, Carette S, Ford P, et al. Osteoarthritis Antirheumatic Drug Trials. III. Setting
35 36		the Delta for Clinical TrialsResults of a Consensus Development (Delphi) Exercise. J
37		
38 39		<i>Rheumatol 19 (3),</i> 1992;3:451-457.
40	48.	Fitzgerald GK, Fritz JM, Childs JD, et al. Exercise, manual therapy, and use of booster
41 42		sessions in physical therapy for knee osteoarthritis: a multi-center, factorial randomized
42		clinical trial. Osteoarthr Cartil. 2016;24(8):1340-1349. doi:10.1016/j.joca.2016.03.001
44 45	49.	Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Editio. (Hillsdale NJ.
46		LE, ed.).; 1998.
47 48	50	
49	50.	Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important
50		differences of rehabilitation intervention with their implications for required sample sizes
51 52		using WOMAC and SF-36 quality of life measurement instruments in patients with
53 54		osteoarthritis of the lower ex. Arthritis Rheum. 2001;45(4):384-391. doi:10.1002/1529-
54 55		0131(200108)45:4<384::AID-ART352>3.0.CO;2-0
56		
57 58		
59		Ear poor ravious only http://hmiapon.hmi.com/cita/about/guidalines.yhtml
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

51. Dobson F, Hinman RS, Roos EM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. *Osteoarthr Cartil.* 2013;21(8):1042-1052. doi:10.1016/j.joca.2013.05.002

For beer terien only

#### Figure 1


Legend: Land Based Exercise Protocol Characteristics

totoeeterien ont

	TIMELINE	Enrolment	STE protocol training	Baseline assessment (A1)	Intervention	Post- intervention assessment (A2)	Follow-up assessment (A3)	Follow-up assessment (A4)
	7	-2 weeks (-14 to -7 day)	-1 week (-7 to 0 day)	Day 0		8 weeks (±3 days)	20 weeks (±3 days)	32 weeks (±3 days)
Enrolment	Eligibility screen Informed consent	x x						
Interventions Assessments	Allocation STE STE + cryotherapy STE + sham cryotherapy X-ray examination of both knees VAS WOMAC SF-36 Timed-up and Go Test 30-Second Chair to Stand Test Stair Climb Test 40m (4x10m) Fast Paced Walk Test	х		X X X X X X X X X X	X X X	X X X X X X X X	X X X X X X X X	X X X X X X X X
-	h Therapeutic Exercises; VAS: Visua ; KOOS: Knee Injury and Osteoarth	-				ities Osteoarthrit	is	
	For p	eer review only - ht	.tp://bmjopen.bmj.	com/site/about/	/guidelines.xhtml			22

 Table 2. Description of the outcome measures.

Description of the test	Scoring	Minimum clinically important difference
The scale is positioned in front of the patient who is asked to evaluate pain intensity in the prior week. <sup>39</sup>	The scale ranges from 0 (no pain) to 10 cm (maximum pain intensity).	A pain reduction of 1.7 cm is recommended in OA research. <sup>47</sup>
This self-report questionnaire evaluates the difficulties experienced by individuals with lower limb OA in the prior 72 hours. It contains 24 questions in 3 domains: pain, stiffness, and physical function.	Each question is scored from 0 to 4, and the maximum score possible is 96. The higher the scores, the worse the status of a patient.	An improvement of 12 <sup>th</sup> from baseline is recommended in OA research. <sup>50</sup>
The participant is positioned in front of the stairs. At the therapist's signal, he/she has to climb the indicated steps (we used the 12-step SCT) and descend promptly, being able to use the handrail as a security instrument. We used 20 cm steps height, a handrail stair in an lighted environment, free of traffic, or external distractions. Moreover, a pre-test was conducted to identify the need for safety measures.	The final score is calculated based on the time the participant took to perform the test and compared it to the literature normative values of the test.	A reduction of 5.5 seconds in the test is th recommended MCID in OA research <sup>42</sup>
Administered at a distance of 10 meters (marked by tapes), a cone is placed 2 meters before the start and 2 meters after the end of each marking. The participant is instructed to walk as quickly but as safely as possible the first 10 meters (from the start mark), to turn around in the cone and walk back the 10 meters again, successively until completing the distance of 40 meters.	Speed (m/s)	An increase of 0.2-0.3 meters per second in th test is the recommende MCID in OA research <sup>4</sup>
A chair with no arms is placed against a wall to prevent oscillations. Patients sit in the middle of the chair, with their back straight and feet resting on the floor in line with their shoulders. The participant is asked to rise from sitting to standing as many times as possible in 30 seconds.	Total number of repetitions within 30 seconds	An increase of 2 to 3 repetitions is recommended in OA research. <sup>51</sup>
	The scale is positioned in front of the patient who is asked to evaluate pain intensity in the prior week. <sup>39</sup> This self-report questionnaire evaluates the difficulties experienced by individuals with lower limb OA in the prior 72 hours. It contains 24 questions in 3 domains: pain, stiffness, and physical function. The participant is positioned in front of the stairs. At the therapist's signal, he/she has to climb the indicated steps (we used the 12-step SCT) and descend promptly, being able to use the handrail as a security instrument. We used 20 cm steps height, a handrail stair in an lighted environment, free of traffic, or external distractions. Moreover, a pre-test was conducted to identify the need for safety measures. Administered at a distance of 10 meters (marked by tapes), a cone is placed 2 meters before the start and 2 meters after the end of each marking. The participant is instructed to walk as quickly but as safely as possible the first 10 meters (from the start mark), to turn around in the cone and walk back the 10 meters again, successively until completing the distance of 40 meters. A chair with no arms is placed against a wall to prevent oscillations. Patients sit in the middle of the chair, with their back straight and feet resting on the floor in line with their shoulders. The participant is asked to rise from sitting to standing as many times as possible in 30	The scale is positioned in front of the patient who is asked to evaluate pain intensity in the prior week. <sup>39</sup> This self-report questionnaire evaluates the difficulties experienced by individuals with lower limb OA in the prior 72 hours. It contains 24 questions in 3 domains: pain, stiffness, and physical function. The participant is positioned in front of the stairs. At the therapist's signal, he/she has to climb the indicated steps (we used the 12-step SCT) and descend promptly, being able to use the handrail as a security instrument. We used 20 cm steps height, a handrail stair in an lighted environment, free of traffic, or external distractions. Moreover, a pre-test was conducted to identify the need for safety measures. Administered at a distance of 10 meters (marked by tapes), a cone is placed 2 meters before the start and 2 meters after the end of each marking. The participant is instructed to walk as quickly but as safely as possible the first 10 meters (from the start mark), to turn around in the cone and walk back the 10 meters again, successively until completing the distance of 40 meters. A chair with no arms is placed against a wall to prevent oscillations. Patients sit in the middle of the chair, with their back straight and feet resting on the floor in line with their shoulders. The participant is aked to rise from sitting to standing as many times as possible in 30



## **SUPPLEMENTARY FILE**

### Land-Based Exercises Protocol for Patients with Knee Osteoarthritis

#### Warm-up Phase (10 min)







Description: treadmill, stationary bicycle, or walking. Performed in a comfortable cardiorespiratory intensity aiming the joints mobility.

### Cool-down Phase (10 min)



**Description: Quadriceps stretching.** Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds



**Description: Gastrocnemius stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds





**Description: Hamstrings stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds

## **SUPPLEMENTARY FILE**

### **Conditioning PHASE 1**

В

57

58 59

60



Α



















#### Name: Bridge

**Type: isometric Position A:** lie down on the mat, knees pointing to the ceiling, knees aligned with hips.

**Position B:** raise your hips up toward the ceiling and hold for 15 up to 30 s. **Sets:** 3 x 15-30 seconds

### Name: Straight Leg Raise (SLR) – hip flexion

#### Type: Isotonic

Position A: lie down, one leg bent and another straight, pull up your foot. Position B: raise your leg straight up until it is aligned with the other thigh, then slowly lower it down. Sets: 3

Repetitions: 12

Name: SLR – hip abduction Type: Isotonic Position A: side lying position, bend the knee in contact with the floor and straight the other leg. Position B: raise your leg straight up, kneecap pointing forward, pulling up your foot. Sets: 3

Repetitions: 12

Name: SLR – hip adduction Type: Isotonic Position A: side lying position, leg in contact with the floor straight and the other leg bent. Position B: raise your leg straight up, kneecap pointing forward, pulling up your foot. Sets: 3

Repetitions: 12

Name: SLR – hip extension Type: Isotonic Position A: prone position, both legs straight touching the floor. Position B: raise one leg up at a time, keeping the totally knee straight. Sets: 3 Repetitions: 12

## **SUPPLEMENTARY FILE**

В

> 18 19 20

21

22

23

24 25

26

27

28

29

37 38 39

40 41 42

43

44

45

46

47

48

49

50 51 52

53

54 55

56

57

58

59


60



Α







#### Name: Abdominal curls (crunchs) Type: Isotonic

**Position A:** lie down on the mat, place your hands behind your head, bend your knees and keep them aligned with hips.

**Position B:** as you exhale, slowly lift your chest up; as you inhale, slowly lower your chest down. Avoid bringing your chin to your chest. **Sets:** 3

Repetitions: 12

Name: Standing calf raises Type: Isotonic Position A: Standing on both legs, hands on the wall for balance (if needed). Position B: rise up on toes then slowly lower down. Sets: 3 Repetitions: 12

### **Conditioning PHASE 2**

В

Α







Name: Plank Type: Isometric Position A: Iying on your belly (prone position). Position B: lift your entire body up with elbow and feet supports. Hold for 15 up to 30 seconds. Sets: 3 x 15-30 seconds

#### Name: Bridge with one leg Type: Isometric

**Position A:** lie down on the mat, knees pointing to the ceiling, knees aligned with hips.

**Position B:** raise your hips up toward the ceiling then carefully take one leg off the floor. Hold for 15 up to 30 s. **Sets:** 3 x 15-30 seconds

## **SUPPLEMENTARY FILE**

В

60



Α











Name: Clam shell Type: Isotonic Position A: side lying position, elastic band around your thighs, knees bent. Position B: move your knee away, squeezing your buttocks then slowly return. Repeat with the other side/leg. Sets: 3

#### Repetitions: 12

Name: Abdominal curls with lifted legs

#### **Type: Isotonic**

Position A: lie down on the mat, place your hands behind your head, bend your knees and keep them aligned with hips. Lift both legs up.
Position B: as you exhale, slowly lift your chest up; as you inhale, slowly lower your chest down. Avoid bringing your chin to your chest.
Sets: 3

Repetitions: 12

#### Name: Trunk extension Type: Isometric Position A: lying on your belly (prone position). Position B: move your chest away from the floor. Look at the ground. Hold for 30 seconds at least. Repetitions: 3 x 30 seconds

#### Name: Wall squat

Type: Isometric contraction Position A: stand with your trunk to a wall, feet aligned with knees and hips, and away from the wall. Position B: slide down and keep your trunk towards the wall. Hold for 30 seconds up to one minute. Repetitions: 3

#### Name: Partial squat Type: isotonic contraction Position A: standing on both legs. Position B: slowly bend your knees and stand up again. Maintain your knees over your feet. Repetitions: 3







## **SUPPLEMENTARY FILE**



Α



В













Name: Standing hip abduction. Type: static balance Position A: standing on both legs with an elastic band around both legs. Position B: lift one leg out, maintain the kneecap pointing forward, and hold for 30 seconds or more. Repetitions: 3 (each leg)

Name: Standing on one leg Type: static balance on stable surface Position A: standing on both legs, eyes opened.

**Position B:** standing on one leg, knee slightly bent, lift the other leg off the floor and maintain the position up to 1 minute.

Repetitions: 2 (each leg)

Name: Standing on one leg Type: static balance on unstable surface (trampoline, foam etc) Position A: standing on both legs, eyes opened. Position B: standing on one leg,

remove another leg from ground and maintain the position. **Repetitions:** 2 (each leg)

#### Name: Step-up

Type: isotonic contraction Position A: on leg onto a step. Position B: step up onto the next step, use the wall for balance if needed. Step back down carefully to the position A. Sets: 2 (each leg) Repetitions: 12

BMJ Open



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	ltem No	n Description			
Administrative in	format	lion			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym – <b>PAGE 01</b>			
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry <mark>– PAGE 02</mark>			
	2b	All items from the World Health Organization Trial Registration Data Set - N/A			
Protocol version	3	Date and version identifier - N/A			
Funding	4	Sources and types of financial, material, and other support - PAGE 14			
Roles and	5a	Names, affiliations, and roles of protocol contributors - PAGE 01			
responsibilities	5b	Name and contact information for the trial sponsor - N/A			
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities - N/A			
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) - N/A			
Introduction					
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention – PAGES 4-5			
	6b	Explanation for choice of comparators – PAGES 4-5			
Objectives	7	Specific objectives or hypotheses <mark>– PAGES 4-</mark> 5			

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (e superiority, equivalence, noninferiority, exploratory) – PAGE 6
Methods: Particip	oants,	interventions, and outcomes
Study setting	9	Description of study settings (eg, community clinic, academic hospit and list of countries where data will be collected. Reference to wher list of study sites can be obtained - PAGE 6
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibil criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) – PAGE 7
Interventions	11a	Interventions for each group with sufficient detail to allow replication including how and when they will be administered - PAGES 8-10
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) – PAGES 8-10
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) – PAGES 8-10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial <mark>– PAGES 8-10</mark>
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy ar harm outcomes is strongly recommended <b>– PAGES 10-11</b>
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins an washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) – PAGE 22
Sample size	14	Estimated number of participants needed to achieve study objective and how it was determined, including clinical and statistical assumptions supporting any sample size calculations – PAGE 12
	15	Strategies for achieving adequate participant enrolment to reach

_			
1 2 3 4 5 6 7 8 9	Sequence generation	16a	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions – PAGE 12
10 11 12 13 14	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned - PAGE 12
15 16 17	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions – PAGE 12
18 19 20 21 22	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how – PAGES 8, 10
23 24 25 26		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial – N/A
27 28	Methods: Data co	llectio	n, management, and analysis
29 30 31 32 33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol <b>– PAGES 12-13</b>
37 38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols – PAGES 12-13
42 43 44 45 46 47 48	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol – PAGE 12-13
49 50 51 52	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol – PAGES 12-13
53 54 55 56		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses) <mark>– PAGES 12-13</mark>
50 57 58 59 60		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) – PAGES 12-13

1 2 3 4 5	
6 7 8 9 10	
11 12 13 14 15 16	
17 18 19 20 21	
22 23 24 25 26 27	
28 29 30 31 32	
33 34 35 36 37	
38 39 40 41 42 43	
44 45 46 47 48	
49 50 51 52 53 54	
55 56 57 58 59	
60	

Methods: Monitoring						
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed N/A				
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial – N/A				
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct – PAGES 6-8				
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor – N/A				
Ethics and dissemination						
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval <mark>– PAGES 13, 14</mark>				
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) – PAGE 13				
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) – PAGE 13				
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable N/A				
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial <b>– PAGES 06, 07</b>				
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site <mark>– PAGE 14</mark>				
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators <b>N/A</b>				
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation N/A				

2 3 4 5 6 7	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions – PAGES 13, 14
8 9 10 11		31b	Authorship eligibility guidelines and any intended use of professional writers N/A
12 13 14		31c	Plans, if any, for granting public access to the full protocol, participant- level dataset, and statistical code <mark>– PAGE S13, 14</mark>
15 16	Appendices		
17 18 19	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates <b>N/A</b>
20 21 22 23 24	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable N/A
24 25	*It is strongly recor	nmenc	ded that this checklist be read in conjunction with the SPIRIT 2013

It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.


# **BMJ Open**

#### CRYOTHERAPY ASSOCIATED WITH TAILORED LAND-BASED EXERCISES FOR KNEE OSTEOARTHRITIS: A PROTOCOL FOR A DOUBLE-BLIND SHAM CONTROLLED RANDOMIZED TRIAL

Journal:	BMJ Open	
Manuscript ID	bmjopen-2019-035610.R2	
Article Type:	Protocol	
Date Submitted by the Author:	11-Mar-2020	
Complete List of Authors:	Ogura Dantas, Lucas; Federal University of Sao Carlos, Physiotherapy Serafim Jorge, Ana Elisa; Federal University of Sao Carlos, Physiotherapy Serrao, Paula; Federal University of Sao Carlos, Physiotherapy Sendín, Francisco; Universidad de Córdoba, Sociosanitary Sciences, Radiology and Physical Medicine, University of Córdoba, Córdoba, Spain and Instituto Maiomónides de Investigación Biomédica de Córdoba (IMIBIC) Salvini, Tania; Federal University of Sao Carlos, Physiotherapy	
<b>Primary Subject Heading</b> :	Rheumatology	
Secondary Subject Heading:	Rheumatology, Rehabilitation medicine	
Keywords:	PAIN MANAGEMENT, REHABILITATION MEDICINE, PUBLIC HEALTH	



BMJ



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

TITLE: CRYOTHERAPY ASSOCIATED WITH TAILORED LAND-BASED EXERCISES
 FOR KNEE OSTEOARTHRITIS: A PROTOCOL FOR A DOUBLE-BLIND SHAM
 CONTROLLED RANDOMIZED TRIAL

Lucas Ogura Dantas<sup>1</sup>, PT; Ana Elisa Serafim Jorge<sup>1</sup>, PT, MSc, PhD; Paula Regina Mendes Silva
Serrao<sup>1</sup>, PT, MSc, PhD; Francisco Alburquerque-Sendín<sup>2</sup>, PT, MSc, PhD; Tania Fatima Salvini<sup>1</sup>,
PT, MSc, PhD.

9 Author Affiliations: <sup>1</sup>Physical Therapy Department, Federal University of São Carlos, São
10 Carlos, Brazil. <sup>2</sup>Sociosanitary Sciences, Radiology and Physical Medicine, University of Córdoba,
11 Córdoba, Spain and Instituto Maiomónides de Investigación Biomédica de Córdoba (IMIBIC),
12 Córdoba, Spain.

14 Corresponding Author: Tania Fatima Salvini, PT, MSc, PhD. Neuromuscular Plasticity
15 Laboratory, Physical Therapy Department, Federal University of São Carlos, Rodovia Washington
16 Luiz, Km 235, CEP:13.565-905, CxP: 676, São Carlos, SP, Brazil (tania@ufscar.br)

## BMJ Open

1	ABSTRACT	

**Introduction:** There is an unmet need to develop tailored therapeutic exercise protocols applying different treatment parameters and modalities for individuals with knee osteoarthritis (KOA). Cryotherapy is widely used in rehabilitation as an adjunct treatment due to its effects on pain and the inflammatory process. However, disagreement between KOA guidelines remains with respect to its recommendation status. The aim of this study is to verify the complementary effects of cryotherapy when associated with a tailored therapeutic exercise protocol on patients with KOA. Methods and analysis: This study is a sham-controlled, randomized trial with concealed allocation and intention-to-treat analysis. Assessments will be performed at baseline and immediately following the intervention period. To check for residual effects of the interventions applied, three- and six-month follow-up assessments will be performed. Participants will be community members living with KOA. There will be three groups: (1) the experimental group that will receive a tailored therapeutic exercise protocol followed by a cryotherapy session of 20 minutes; (2) the sham control group that will receive the same regimen as the first group, but with sham packs filled with dry sand; and (3) the active treatment control group that will receive only the therapeutic exercise protocol. The primary outcome will be pain intensity according to a Visual Analogue Scale. Secondary outcomes will be the Western Ontario & McMaster Universities Osteoarthritis Index; the Medical Outcomes Survey Short-Form 36 questionnaire; the 30-Second Chair Stand Test; the Stair Climb test; and the 40-Meter fast-paced walk test.

20 Ethics and dissemination: The trial was approved by the Institutional Ethics Committee of
21 Federal University of Sao Carlos, São Paulo, Brazil. Registration approval number: CAAE:
22 65966617.9.0000.5504. The results will be published in peer-reviewed journals.

23 Trial registration number: NCT03360500

2 3	1	Strengths and limitations of this study:
4 5	2	<ul> <li>The trial will be conducted according to well-established reporting guidelines.</li> </ul>
6 7	3	<ul> <li>Participants will present with radiographically confirmed knee osteoarthritis and a</li> </ul>
8 9 10		
10 11 12	4	sufficient level of pain to ensure ample scope for improvement.
12 13 14	5	<ul> <li>The trial will use both subjective and objective outcome measures.</li> </ul>
15 16	6	• The therapist who delivers cryotherapy or the sham intervention and the patients will not
17 18	7	be blinded.
19 20	8	• The loss to follow-up after randomization in the sham group might be higher than those in
21 22	9	the other groups.
23 24	10	
25 26	11	
27 28	12	
29 30	13	
31 32 33		The loss to follow-up after randomization in the sham group might be higher than those in the other groups.
34 35	14	
36 37	15	
38 39	16	
40 41	17	
42 43		
44 45		
46 47 48		
48 49 50		
50 51 52		
53 54		
55 56		
57 58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

Knee osteoarthritis (KOA) is a serious disease with a high societal and economic burden,<sup>1</sup> affecting approximately 250 million people worldwide.<sup>2</sup> Current clinical practice guidelines recommend a combination of pharmacological<sup>3</sup> and non-pharmacological<sup>4</sup> treatment strategies to manage KOA symptoms and improve patients' quality of life. However, pharmacological treatment options that have been proven to relieve symptoms remain limited, and some of the most commonly recommended pharmacologic treatments are poorly tolerated, with long-term use resulting in serious systemic adverse events.<sup>5–7</sup>

Physical Therapy, specifically the use of strengthening therapeutic exercise (STE) protocols, have been shown to relieve pain, reduce stiffness, increase physical function, and improve quality of life in patients with KOA.<sup>1,8</sup> High-quality evidence has demonstrated that the benefits of STE protocols on pain and quality of life in individuals with KOA are sustained for at least two to six months after the end of a treatment.<sup>8</sup> There is, however, a call for further research to develop novel insights within STE protocols regarding differences in treatment durations, frequencies, modalities, and intensities.<sup>9</sup> The majority of current protocols have reported low adherence and are substantially under-utilized by KOA patients, mainly due to socioeconomic barriers, personal beliefs, fear of movement, and aggravation of pain in the early phases of treatment.<sup>10,11</sup> Therefore, there is an unmet need for cost-effective, evidence-based STE protocols that are tailored to the needs of KOA patients, and that can aid clinicians in targeting rehabilitation goals.

Physical modalities such as thermal agents, laser therapy, therapeutic ultrasound, and electrical
 stimulation are often used as adjunct treatments with therapeutic exercises in individuals with
 KOA.<sup>4,12</sup> Cryotherapy, a non-pharmacological intervention, has been widely used in some

rheumatic joint diseases<sup>13,14</sup> based on its effects on pain, inflammation, and edema.<sup>15,16</sup> The intervention is considered safe, and is inexpensive and easy to administer for healthcare professionals and patients. Moreover, it can be prescribed in isolation or as an adjunct treatment and seems to be well accepted by individuals with KOA.<sup>14,17,18</sup> Although cryotherapy is recommended as a treatment option by some international KOA guidelines,<sup>19,20</sup> others have found insufficient evidence to support it.<sup>21–23</sup> Relevant systematic reviews have likewise concluded that further evidence, produced with greater methodological rigor, is needed to evaluate the effects of cryotherapy on pain, function, and quality of life in individuals with KOA.<sup>16,24</sup> 

In this study, we aim to design a randomized trial to verify the complementary effects of cryotherapy in conjunction with a tailored STE protocol on pain, function, and quality of life in individuals with KOA. We hypothesize that cryotherapy combined with the STE protocol will achieve better treatment effects on KOA patients when compared to the other two groups. The proposed trial will contribute new evidence to the Physical Therapy field in KOA by focusing on interventions that target rehabilitation and enhance pain management, thereby improving the physical function and quality of life of these patients. Our research group developed the STE protocol described in this study. The protocol was also used in another randomized trial testing the complementary effects of Photobiomodulation in individuals with KOA (trial registration number at www.ensaiosclinicos.gov.br: U1111-1215-6510). This manuscript has been submitted simultaneously with the manuscript entitled "Photobiomodulation therapy associated with supervised therapeutic exercises for people with knee osteoarthritis: a protocol for randomized trials" (ID bmjopen-2019-035711).

#### **BMJ** Open

## 1 METHODS

To report this study protocol, we followed the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT),<sup>25</sup> the Osteoarthritis Research Society International clinical trials recommendations: design, conduct, and reporting of clinical trials for knee osteoarthritis,<sup>26</sup> and the Template for Intervention Description and Replication checklist (TIDieR).<sup>27</sup> The randomized trial will be reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement for randomized trials of non-pharmacologic treatments.<sup>28</sup> The trial is registered on the clinicaltrials.gov (NCT03360500) platform.

## 10 Study design and setting

This study is a single-center, sham-controlled randomized clinical trial. A baseline assessment (A1) will be performed on the weekday before the 8-week intervention period, and a postintervention assessment (A2) will be performed immediately following the last session. To check for residual effects of the interventions, three-month (A3) and six-month (A4) follow-up assessments will be performed. Each patient will be assessed in a physiotherapy research laboratory, during the same period of the day and by the same assessor. To reduce bias, the therapists responsible for applying the intervention and the outcome assessors will follow standardized scripts that describe the general objective of the study.<sup>26</sup> 

Intervention adherence, medication intake, and adverse events will be tracked with an 8-week assessment diary that will be given to participants at the baseline assessment and with a 12-week assessment diary for the three-month follow-up assessment. All the participants will be advised not to practice any other type of regular physical exercise during the course of the study that could

interfere with the STE protocol. A verbal and written explanation of the objectives and methodology of the study will be provided to all the participants, and those willing to participate will sign a written informed consent form, approved by the local ethics committee. A detailed timeline of the trial is presented in **Table 1**.

## 6 Patient and Public Involvement

The patients and the public were not involved in the planning and design of this study.

## **Participants**

Participants will be recruited through public announcements on social media, advertisements via local news outlets, University community newsletters, and banners or leaflets posted at strategic locations in the city. People who are interested in participating in the study will first be screened to check the eligibility criteria. Eligible participants will then undergo a lateral, anteroposterior, and axial radiography of both knees to determine KOA severity, which will take place at the University Hospital. Participants will be classified with KOA based on the clinical and radiographic criteria of the American College of Rheumatology,<sup>29</sup> and will be required to have symptoms and a radiographic grade (Kellgren and Lawrence scale) of  $\geq 2$  (mild radiographic OA) in at least one knee compartment.<sup>26</sup> 

To be included in the study, participants will also need to: be between 40 and 75 years old; be engaged in a total of less than 45 minutes/week of physical activity of at least moderate intensity<sup>30</sup>; have a body mass index  $<35 \text{ kg/m}^2$ ; and to have reported pain intensity in the prior week of  $\geq$ 4 cm on a 10-cm visual analogue scale.<sup>26</sup> Exclusion criteria will comprise physical therapy in the prior

#### **BMJ** Open

three months; intra-articular knee injections in the prior six months; medical restrictions such as cardiorespiratory, neurological, or any other rheumatology conditions; previous hip, knee, or ankle surgery; and any other chronic condition that leads to chronic pain or dysfunction. Additionally, participants presenting with contraindication(s) to cryotherapy application (i.e., those that feel a high level of discomfort or pain during the application) will be excluded.

All the participants will be asked to provide a medical certificate stating that they are healthyenough to perform physical activities before the start of the intervention.

9 Interventions

The intervention protocol is based on a previously accepted methodology developed in our research laboratory.<sup>31</sup> Two physical therapists will administer the interventions in the physiotherapy clinic of the University. The study will take place over the course of eight weeks, with three 90-minute sessions per week occurring on non-consecutive days, for a total of 24 sessions. All randomized participants will perform the STE protocol and then, according to random allocation, each patient will subsequently receive either cryotherapy or sham interventions in individual rooms.

Prior to the beginning of the study, the therapists responsible for the interventions will participate in a 10-hour training module, which will consist of scientific information and clinical training regarding KOA, the STE protocol, and the use of cryotherapy. After the first training module is completed, the therapists will do an eight-week training module, which will consist of practicing the full-length protocol and intervention application(s) three times per week. Both therapists will be responsible for delivering cryotherapy and sham interventions.

## 1 <u>STE protocol</u>

We designed the 8-week land-based supervised exercise protocol according to the evidence-based recommendations for physical exercise interventions in KOA.<sup>32,33</sup> The STE protocol characteristics are described in Figure 1, and a detailed description of all the exercises is presented in the **Supplementary file** of this protocol. The protocol is divided into two phases. Each phase consists of 4 weeks of progressive exercises, performed three times per week on non-consecutive days (24 hours rest between sessions), with exercise intensity individually tailored for each participant. The first session is used to demonstrate and explain the STE protocol, and to perform an exercise familiarization using no loads by the participants. The second session is designed to estimate the initial resistance of each participant for each exercise. The volitional interruption method is used in order to achieve the benefits of resistance training and to reduce the risk of musculoskeletal injuries to the participants.<sup>34</sup> The loads are gradually increased until the participant can adequately perform 12 repetitions with no voluntary interruption due to muscle fatigue.

The STE protocol sessions consist of three phases. The first phase is a 10-minute warm-up in which the patients can choose, according to their preferences, to walk in a comfortable intensity in an outdoor circuit, treadmill, or ride in a stationary bicycle. The second phase consists of 40 minutes of strengthening exercises (resistance training), such as a lower limb and trunk muscles, and neuromuscular training involving balance exercises. The third phase is a cool-down phase, consisting of static stretching exercises to reduce the risk of musculoskeletal injuries and to maximize the benefit of the STE protocol.<sup>35</sup> Cardiac and respiratory frequencies and blood pressure are monitored at the beginning of each session or if the participant presents an intense

### **BMJ** Open

rate of perceived exertion according to the Borg scale while performing an exercise, to ensure
 patient safety.<sup>36,37</sup>

## 4 Cryotherapy protocol

To apply cryotherapy, the therapist will explain to the patient that the intervention will consist of crushed ice applied to the more-affected knee for 20 minutes. Participants will be positioned in dorsal decubitus with both legs extended and relaxed. The entire knee surface will be covered with a moist surgical gauze ( $45 \times 50 \times 0.01$  cm) to protect the skin from possible frostbite. Next, two plastic bags  $(24 \times 34 \times 0.08 \text{ cm})$ , each containing 1 kg of crushed ice, will be placed on the knee, covering the anterior, posterior, medial, and lateral surfaces. A comfortable, non-painful compression will be applied over the ice packs by wrapping an elastic bandage around them, and the therapy will be left in situ, uninterrupted, for 20 minutes. The primary purpose of compression is to maintain the ice packs in position on the knee<sup>38</sup> and to enhance cryotherapy effects.<sup>39</sup> 

For the sham cryotherapy intervention, the bags will be filled with 1 kg of dry sand instead of ice. The sandbags will be applied according to the same regimen in the same locations. The therapist's explanation about the intervention will be changed to mention the 'application of sand packs' instead of 'cryotherapy application.' The sandbags will be applied with the same gauze underneath and the same bandage for compression.

## **Outcome measures**

The same blinded assessor will measure all outcomes before and after the intervention, and at the 3- and 6-month follow-up periods. Before the study begins, the two outcome assessors will be

trained to conduct interviews and perform data collection following a standard protocol. **Table 2** describes the outcome measures that will be included in the trial and the recommended estimate of the minimum clinically important difference (MCID) for each outcome measure. We will measure pain intensity, subjective and objective physical function, and quality of life.

*Primary outcome* 

7 The primary outcome will be pain intensity at rest, assessed with a Visual Analogue Scale (VAS).
8 This self-reported pain score is a valid and reliable measure for KOA.<sup>40</sup> The VAS will be
9 administered at rest and after each physical function test, occurring at baseline, on the final
10 assessment day, and at the 3- and 6-month follow-up periods.

## 12 Secondary outcomes

To subjectively assess physical function and associated problems, the Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) will be used. WOMAC is a frequently used questionnaire in KOA and is translated, reproducible, and valid to Brazilian Portuguese.<sup>41</sup> The Medical Outcomes Survey Short-Form 36 (SF-36) questionnaire will be used to asses quality of life. The questionnaire is translated, reproducible, and valid to use in Brazilian Portuguese.<sup>42</sup> Three objective physical function tests will also be used: The 30-Second Chair Stand test, the Stair Climb test, and the 40-Meter fast-paced walk test. The questionnaires and physical function tests described are well-established core assessment measures of pain and physical function in patients with KOA, and presenting good scores for reliability, validity, and ability to detect change.<sup>43–47</sup> 

### BMJ Open

## 1 Randomization

Eligible patients who consent to participate will be randomly allocated into three groups of 40: (1) active control group that will receive the STE protocol only, (2) STE + cryotherapy group, and (3) STE + sham cryotherapy group. The allocation of patients will be performed using permuted block randomization stratified by gender (20 men and 20 women in each group); randomization sequences will be determined by a computer-generated random numbers program (www.randomization.com). Allocation will be concealed by placing randomization assignments in opaque sealed envelopes that will be locked in a central location. A biostatistician will be responsible for generating the random numbers and each participant's random allocation will be revealed to the therapist administering the intervention just before study onset.<sup>26</sup> 

## 

## 12 Sample size

We aim to detect a minimum clinically important difference (MCID) of 1.75 cm units on the VAS for pain intensity at rest.<sup>48</sup> Also, we aim to detect an MCID of 30 points on the WOMAC global score.<sup>49</sup> Calculations were based on an analysis of covariance adjusting for baseline outcome scores, assuming between-patient standard deviations of 2.0 cm for pain and 45 points for WOMAC global score. Based on these criteria, to achieve a significance level of 0.05 and a power of 0.80%, 37 participants with KOA will be required in each group. We will recruit 40 participants per group to allow possible dropouts during the intervention period.

## 21 Data analysis

The analyses will be performed by a blinded biostatistician using commercial software. The
Kolmogorov-Smirnov test will be applied to evaluate the normality of data distribution. If the

distribution is not normal, non-parametric tests will be used. For normal distributions, a 2-factor analysis of variance (ANOVA) will be conducted for the primary outcome (visual analogue scale for pain) and secondary outcomes, with time (baseline, post-intervention, and follow-up) as the within-subject factor and group (STE, STE + cryotherapy, STE + sham cryotherapy) as the between-subject factor. In addition, Tukey's test will be used for post-hoc analysis when necessary, and an intention-to-treat analysis will be performed for all randomized participants. All the missing data will be replaced using the expectation-maximization method. Between-group differences and their 95% confidence intervals will be reported and interpreted against the nominated thresholds for MCID. For the outcomes where the MCID is not nominated, Cohen's *d* coefficient will be calculated to aid interpretation. An effect size greater than 0.8 will be considered large, around 0.5 moderate, and less than or equal to 0.2, small<sup>50</sup>.

## 13 ETHICS AND DISSEMINATION

The Institutional Ethics Committee of the Federal University of Sao Carlos, São Paulo, Brazil, approved the under the registration approval number: CAAE: 65966617.9.0000.5504. The trial will be conducted according to the Helsinki Statement. All participants will provide written informed consent following a verbal and written explanation of the study protocol. Participants will be free to withdraw from the trial at any time without prejudice to future treatment. Results will be presented at scientific meetings and published in peer-reviewed journals. All publications and presentations related to the study will be authorized and reviewed by the study investigators.

BMJ Open

2		
3	1	TRIAL STATUS
4 5		
6 7	2	The trial is currently recruiting and is expected to be completed (including follow-up testing) by
, 8 9	3	December 2020.
) 10 11	4	
12 13	5	AUTHORS CONTRIBUTION
14 15 16	6	L.O.D., A.E.S.J., P.R.S., F.A.S., and T.F.S. designed the study protocol. L.O.D. wrote the first
16 17 18	7	draft of the manuscript, and together with A.E.S.J., P.R.S., F.A.S., and T.F.S. revised and produced
19 20	8	the final version. All authors have read and approved the final version of the manuscript. L.O.D.
21 22	9	takes responsibility for the integrity of the work as a whole.
23 24	10	
25 26 27	11	FUNDING
28 29	12	LOD and AESJ were financially supported by Sao Paulo Research Foundation (FAPESP, Process
30 31 32	13	numbers #2018/23705-3, and #2017/00062-7 respectively) and Conselho Nacional de
33 34	14	Desenvolvimento Científico e Tecnológico (CNPQ # 401333/2016-7).
35 36	15	
37 38 39	16	DISCLAIMER
40 41	17	The study funders have had no role in study design; collection, management, analysis and
42 43	18	interpretation of data; writing of the report; or the decision to submit the report for publication,
44 45 46	19	and do not own ultimate authority over any of these activities.
46 47 48	20	
49 50	21	COMPETING INTERESTS
51 52 53 54 55 56 57 58	22	All authors have completed a uniform disclosure form and declare no conflicts of interest
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## REFRENCES

Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet (London, England)*.
 2019;393(10182):1745-1759. doi:10.1016/S0140-6736(19)30417-9

 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2163-2196. doi:10.1016/S0140-6736(12)61729-2

- Mandl LA. Osteoarthritis year in review 2018: clinical. *Osteoarthr Cartil.* 2018;(xxxx):1 6. doi:10.1016/j.joca.2018.11.001
- 4. Collins NJ, Hart HF, Mills KAG. OARSI year in review 2018: rehabilitation and outcomes. *Osteoarthr Cartil*. 2018;0(0). doi:10.1016/j.joca.2018.11.010
- Vowles KE, Mcentee ML, Siyahhan P, Frohe T, Ney JP, Goes DN Van Der. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain.* 2015;156(4). http://www.nejm.org/doi/10.1056/NEJMra1507771.
- Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain Misconceptions and Mitigation Strategies. N Engl J Med. 2016;374(13):1253-1263. doi:10.1056/NEJMra1507771
- Deveza LA, Hunter DJ, Van Spil WE. Too much opioid, too much harm. Osteoarthr Cartil. 2018;26(3):293-295. doi:10.1016/j.joca.2017.12.003
- Fransen M, Mcconnell S, Ar H, M VDE, Simic M, Kl B. Exercise for osteoarthritis of the knee. *Cochrane Libr*. 2015;(1):1-144. doi:10.1002/14651858.CD004376.pub3.www.cochranelibrary.com
- 9. Lee AC, Harvey WF, Price LL, et al. Dose-Response Effects of Tai Chi and Physical Therapy Exercise Interventions in Symptomatic Knee Osteoarthritis. *PM&R*.
  - 2018;10(7):712-723. doi:10.1016/j.pmrj.2018.01.003
- Nicolson PJAA, Bennell KL, Dobson FL, Van Ginckel A, Holden MA, Hinman RS. Interventions to increase adherence to therapeutic exercise in older adults with low back pain and/or hip/knee osteoarthritis: a systematic review and meta-analysis. *Br J Sports Med.* 2017;51(10):791-799. doi:10.1136/bjsports-2016-096458
- Dobson F, Bennell KL, French SD, et al. Barriers and Facilitators to Exercise Participation in People with Hip and/or Knee Osteoarthritis. *Am J Phys Med Rehabil*.

60

## BMJ Open

1 2		
3		2016;95(5):1. doi:10.1097/phm.00000000000448
4 5	12.	Oo WM, Thae Bo M. Efficacy of Physical Modalities in Knee Osteoarthritis: Recent
6 7		Recommendations. Int J Phys Med Rehabil. 2016;04(03):3-4. doi:10.4172/2329-
8		9096.1000e112
9		
10 11	13.	Demoulin C, Vanderthommen M. Cryotherapy in rheumatic diseases. Jt Bone Spine.
12		2012;79(2):117-118. doi:10.1016/j.jbspin.2011.09.016
13 14	14.	Guillot X, Tordi N, Mourot L, et al. Cryotherapy in inflammatory rheumatic diseases: A
15		systematic review. Expert Rev Clin Immunol. 2014;10(2):281-294.
16 17		doi:10.1586/1744666X.2014.870036
18	1.5	
19 20	15.	Bleakley CM, Davison GW. Cryotherapy and inflammation: evidence beyond the cardinal
20		signs. Phys Ther Rev. 2010;15(6):430-435. doi:10.1179/1743288X10Y.0000000014
22 23	16.	Dantas LO, Moreira R de FC, Norde FM, Mendes Silva Serrao PR, Alburquerque-Sendín
23 24		F, Salvini TF. The effects of cryotherapy on pain and function in individuals with knee
25		osteoarthritis: a systematic review of randomized controlled trials. <i>Clin Rehabil</i> . April
26 27		
28		2019:026921551984040. doi:10.1177/0269215519840406
29 30	17.	Porcheret M, Jordan K, Jinks C. Primary care treatment of knee pain - A survey in older
31		adults. Rheumatology. 2007;46(11):1694-1700. doi:10.1093/rheumatology/kem232
32 33	18.	Denegar CR, Dougherty DR, Friedman JE, et al. Preferences for heat, cold, or contrast in
34		patients with knee osteoarthritis affect treatment response. Clin Interv Aging. 2010;5:199-
35 36		206. doi:10.2147/CIA.S11431
37	10	
38 39	19.	Chae KJ, Choi MJ, Kim KY, Ajayi FF, Chang IS, Kim IS. National Institute for Health
40		and Care Excellence. Osteoarthritis: Care and Management. December 2014.
41 42	20.	Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012
42 43		recommendations for the use of nonpharmacologic and pharmacologic therapies in
44		osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-474.
45 46		
47		doi:10.1002/acr.21596
48 49	21.	McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical
50		management of knee osteoarthritis. Osteoarthr Cartil. 2014;22(3):363-388.
51 52		doi:10.1016/j.joca.2014.01.003
53	22.	Fernandes L, Hagen KB, Bijlsma JWJJ, et al. EULAR recommendations for the non-
54 55		
56		pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis.
57 58		
58 59		16
<u> </u>		For peer review only - http://bmiopen.hmi.com/site/about/quidelines.yhtml

4 5

6

7 8

9 10

11

12 13

14 15

16 17

18

19 20

21 22

23

24 25

26 27

28 29

30

31 32

33 34

35 36

37

38 39

40 41

42

43 44

45 46

47 48

49

50 51

52 53

54 55

60

2013;72(7):1125-1135. doi:10.1136/annrheumdis-2012-202745 23. Brosseau L, Taki J, Desjardins B, et al. The Ottawa panel clinical practice guidelines for the management of knee osteoarthritis. Part two: strengthening exercise programs. Clin *Rehabil*. 2017;31(5):596-611. doi:10.1177/0269215517691084 24. Brosseau L, Yonge K a, Robinson V, et al. Thermotherapy for treatment of osteoarthritis. Cochrane Database Syst Rev. 2003;(4):CD004522. doi:10.1016/S0031-9406(05)60490-7 25. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med. 2013;158(3):200. doi:10.7326/0003-4819-158-3-201302050-00583 26. McAlindon TE, Driban JB, Henrotin Y, et al. OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis. Osteoarthr Cartil. 2015;23(5):747-760. doi:10.1016/j.joca.2015.03.005 27. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348(mar07 3):g1687. doi:10.1136/bmj.g1687 28. Barbour V, Bhui K, Chescheir N, et al. CONSORT Statement for randomized Trials of nonpharmacologic treatments: A 2017 update and a CONSORT extension for nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. doi:10.7326/M17-0046 29. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039-1049. doi:10.1002/art.1780290816 30. Dunlop DD, Song J, Lee J, et al. Physical Activity Minimum Threshold Predicting Improved Function in Adults With Lower-Extremity Symptoms. Arthritis Care Res. 2017;69(4):475-483. doi:10.1002/acr.23181 31. Dantas LO, Breda CC, da Silva Serrao PRM, et al. Short-term cryotherapy did not substantially reduce pain and had unclear effects on physical function and quality of life in people with knee osteoarthritis: a randomised trial. J Physiother. 2019;65(4):215-221. doi:10.1016/j.jphys.2019.08.004 32. Messier SP, Mihalko SL, Beavers DP, et al. Strength training for arthritis trial (START):

1		
2 3		Design and rationals BMC Musculosholat Discurd 2012:14(1):1 doi:10.1186/1471.2474
4		Design and rationale. BMC Musculoskelet Disord. 2013;14(1):1. doi:10.1186/1471-2474-
5 6		14-208
7	33.	Fransen M, McConnell S, Harmer AR, Van Der Esch M, Simic M, Bennell KL. Exercise
8 9		for osteoarthritis of the knee: A Cochrane systematic review. Br J Sports Med.
9 10		2015;49(24):1554-1557. doi:10.1136/bjsports-2015-095424
11	24	Nóbrega SR, Ugrinowitsch C, Pintanel L, Barcelos C, Libardi CA. Effect of Resistance
12 13	34.	
14		Training to Muscle Failure vs. Volitional Interruption at High- and Low-Intensities on
15 16		Muscle Mass and Strength. J Strength Cond Res. 2018;32(1):162-169.
17		doi:10.1519/JSC.000000000001787
18 19	35.	Bennell KL, Dobson F, Hinman RS. Exercise in osteoarthritis: Moving from prescription
20		to adherence. Best Pract Res Clin Rheumatol. 2014;28(1):93-117.
21 22		doi:10.1016/j.berh.2014.01.009
23	26	
24 25	36.	American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription
26		for older adults with osteoarthritis pain: consensus practice recommendations. A
27 28		supplement to the AGS Clinical Practice Guidelines on the management of chronic pain in
29		older adults. Jags. 2001;49(6):808-823. doi:10.1046/j.1532-5415.2001.00496.x
30 31	37.	Vincent KR, Vincent HK. Resistance exercise for knee osteoarthritis. PMR. 2012;4(5
32		Suppl):S45-52. doi:10.1016/j.pmrj.2012.01.019
33 34	20	Silva P, Lott R, Wickrama S, Mota J, Welk G. Elastic Bandaging for Orthopedic and
35	38.	
36 37		Sports Injuries Prevention and Rehabilitation: A Systematic Review. Int J Sport Nutr
38		<i>Exerc Metab</i> . 2016;32:1-44. doi:10.1123/ijspp.2015-0012
39 40	39.	Song M, Sun X, Tian X, et al. Compressive cryotherapy versus cryotherapy alone in
41		patients undergoing knee surgery: a meta-analysis. Springerplus. 2016;5(1):1-12.
42 43		doi:10.1186/s40064-016-2690-7
44	40.	Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog
45 46	40.	
47		Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain
48 49		Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain
50		Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. Arthritis Care Res
51 52		(Hoboken). 2011;63(S11):S240-S252. doi:10.1002/acr.20543
53	41.	MI F. Tradução e validação do questionário de qualidade de vida específico para
54 55		osteoartrose WOMAC (Western Ontario McMaster Universities) para a língua portuguesa.
56		
57 58		
59		18 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60		i or peer review only intep.//binjopen.binj.com/site/about/guidemies.xittim

2003.

- 42. Ciconelli RM, Ferraz MB, Santos W, Meinao I, Quaresma MR. Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure. *Rev Bras Reumatol.* 1999;39(3):143-150.
- 43. Dobson F, Bennell KL, Hinman RS, Abbott JH, Roos EM. Recommended performance based tests to assess physical function in people diagnosed with hip or knee osteoarthritis.
   OARSI Osteoarthr Res Soc Int. 2013:1-26. doi:10.1016/j.joca.2013.05.002
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Rheumatol*. 2020;0(November):art.41142. doi:10.1002/art.41142
- 45. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthr Cartil.* 2019;27(11):1578-1589. doi:10.1016/j.joca.2019.06.011
- 46. Pham T, van der Heijde D, Altman R., et al. OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. *Osteoarthr Cartil.* 2004;12(5):389-399. doi:10.1016/j.joca.2004.02.001
- 47. Bennell K, Dobson F, Hinman R. Measures of physical performance assessments: Self-Paced Walk Test (SPWT), Stair Climb Test (SCT), Six-Minute Walk Test (6MWT), Chair Stand Test (CST), Timed Up & amp; Go (TUG), Sock Test, Lift and Carry Test (LCT), and Car Task. *Arthritis Care Res (Hoboken)*. 2011;63(S11):S350-S370. doi:10.1002/acr.20538
- Bellamy N, Carette S, Ford P, et al. Osteoarthritis Antirheumatic Drug Trials. III. Setting the Delta for Clinical Trials--Results of a Consensus Development (Delphi) Exercise. J Rheumatol 19 (3), 1992;3:451-457.
- 49. Fitzgerald GK, Fritz JM, Childs JD, et al. Exercise, manual therapy, and use of booster sessions in physical therapy for knee osteoarthritis: a multi-center, factorial randomized clinical trial. *Osteoarthr Cartil*. 2016;24(8):1340-1349. doi:10.1016/j.joca.2016.03.001
- 50. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd Editio. (Hillsdale NJ. LE, ed.).; 1998.
- 51. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important

#### **BMJ** Open

differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower ex. Arthritis Rheum. 2001;45(4):384-391. doi:10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0

- Escobar A, Quintana JM, Bilbao A, Aróstegui I, Lafuente I, Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement. Osteoarthr Cartil. 2007;15(3):273-280. doi:10.1016/j.joca.2006.09.001
- Dobson F, Hinman RS, Roos EM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. Osteoarthr Cartil. 2013;21(8):1042-1052. doi:10.1016/j.joca.2013.05.002

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Figure 1

Legend: Land Based Exercise Protocol Characteristics

totoeeteriewony


47

BMJ Open

	TIMELINE	Enrolment	STE protocol training	Baseline assessment (A1)	Intervention	Post- intervention assessment (A2)	Follow-up assessment (A3)	Follow-up assessment (A4)
	A A	-2 weeks (-14 to -7 day)	-1 week (-7 to 0 day)	Day 0		8 weeks (±3 days)	20 weeks (±3 days)	32 weeks (±3 days)
Enrolment	Eligibility screen Informed consent	X X						
Interventions	Allocation			X	₹7			
	STE STE + cryotherapy				X X			
	STE + sham cryotherapy				X X			
	X-ray examination of both knees	X						
Assessments	VAS WOMAC			XX		X	X	X
	SF-36			X		X X	X X	X X
	Timed-up and Go Test			X		X	X	X
	30-Second Chair to Stand Test			Χ		X	Х	Х
	Stair Climb Test			X		X	X	X
	40m (4x10m) Fast Paced Walk Test			X		X	X	Х
STE: Strengtł	Therapeutic Exercises; VAS: Visu	al Analogue Scale	, WOMAC: West	ern Ontario & N	AcMaster Univers	ities Osteoarthrit	İS	
questionnaire	; KOOS: Knee Injury and Osteoarth	ritis Outcome Sco	re; SF-36: Short F	Form-36 questic	nnaire.			
A: Assessmen	nt							
	For s	beer review only - ht		.com/site/about/	guidelines.xhtml			22

## Table 2. Description of the outcome measures.

		Scoring	Minimum clinically important difference
Visual analogue scale	The scale is positioned in front of the patient who is asked to evaluate pain intensity in the prior week. <sup>40</sup>	The scale ranges from 0 (no pain) to 10 cm (maximum pain intensity).	A pain reduction of 1.75 cr is recommended in OA research. <sup>48</sup>
Western Ontario & McMaster Universities Osteoarthritis questionnaire	This self-report questionnaire evaluates the difficulties experienced by individuals with lower limb OA in the prior 72 hours. It contains 24 questions in 3 domains: pain, stiffness, and physical function.	Each question is scored from 0 to 4, and the maximum score possible is 96. The higher the scores, the worse the status of a patient.	An improvement of 12% from baseline is recommended in OA research. <sup>51</sup>
Short Form-36 questionnaire (SF-36)	The short form questionnaire is intended to measure the patient's quality of life with 36 items referring to the past four weeks. It presents a multiple-choice scale that evaluates eight domains of life: Physical Functioning, Role Limitations due to Physical Problems, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, General Mental Health and Health Transition.	The sum of the total value varies from 0 to 100, with higher indexes indicating a better quality of life. Each of the eight summed scores was linearly transformed into a scale from 0 (negative health) to 100 (positive health) to provide a score for each subscale. Each subscale was used independently.	A difference of 10 points i recommended as an MCIE in OA research. <sup>52</sup>
Stair Climb Test	The participant is positioned in front of the stairs. At the therapist's signal, he/she has to climb the indicated steps (we used the 12-step SCT) and descend promptly, being able to use the handrail as a security instrument. We used 20 cm steps height, a handrail stair in an lighted environment, free of traffic, or external distractions. Moreover, a pre-test was conducted to identify the need for safety measures.	The final score is calculated based on the time the participant took to perform the test and compared it to the literature normative values of the test.	A reduction of 5.5 seconds in the test is the recommended MCID in O research <sup>43</sup>
40m (4x10m) Fast Paced Walk Test	Administered at a distance of 10 meters (marked by tapes), a cone is placed 2 meters before the start and 2 meters after the end of each marking. The participant is instructed to walk as quickly but as safely as possible the first 10 meters (from the start mark), to turn around in the cone and walk back the 10 meters again, successively until completing the distance of 40 meters.	Speed (m/s)	An increase of 0.2-0.3 meters per second in the test is the recommended MCID in OA research <sup>43</sup>
30-Second Chair to Stand Test	A chair with no arms is placed against a wall to prevent oscillations. Patients sit in the middle of the chair, with their back straight and feet resting on the floor in line with their shoulders. The participant is asked to rise from sitting to standing as many times as possible in 30 seconds.	Total number of repetitions within 30 seconds	An increase of 2 to 3 repetitions is recommended in OA research. <sup>53</sup>



# **SUPPLEMENTARY FILE**

## Land-Based Exercises Protocol for Patients with Knee Osteoarthritis

## Warm-up Phase (10 min)







Description: treadmill, stationary bicycle, or walking. Performed in a comfortable cardiorespiratory intensity aiming the joints mobility.

## Cool-down Phase (10 min)



**Description: Quadriceps stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds



**Description: Gastrocnemius stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds





**Description: Hamstrings stretching**. Active stretching performed with maximum tolerable range of motion.

Set: 1 x 30 seconds

# **SUPPLEMENTARY FILE**

## **Conditioning PHASE 1**

В

57

58 59

60



Α



















## Name: Bridge

**Type: isometric Position A:** lie down on the mat, knees pointing to the ceiling, knees aligned with hips.

**Position B:** raise your hips up toward the ceiling and hold for 15 up to 30 s. **Sets:** 3 x 15-30 seconds

## Name: Straight Leg Raise (SLR) – hip flexion

### **Type: Isotonic**

**Position A:** lie down, one leg bent and another straight, pull up your foot. **Position B:** raise your leg straight up until it is aligned with the other thigh, then slowly lower it down. **Sets:** 3

Repetitions: 12

Name: SLR – hip abduction Type: Isotonic Position A: side lying position, bend the knee in contact with the floor and straight the other leg. Position B: raise your leg straight up, kneecap pointing forward, pulling up your foot. Sets: 3

Repetitions: 12

Name: SLR – hip adduction Type: Isotonic Position A: side lying position, leg in contact with the floor straight and the other leg bent. Position B: raise your leg straight up, kneecap pointing forward, pulling up your foot. Sets: 3

Repetitions: 12

Name: SLR – hip extension Type: Isotonic Position A: prone position, both legs straight touching the floor. Position B: raise one leg up at a time, keeping the totally knee straight. Sets: 3 Repetitions: 12

# **SUPPLEMENTARY FILE**

В

> 18 19 20

21

22

23

24 25

26

27

28

29

37 38 39

40 41 42

43

44

45

46

47

48

49

50 51 52

53

54 55

56

57

58

59


60



Α







## Name: Abdominal curls (crunchs) Type: Isotonic

**Position A:** lie down on the mat, place your hands behind your head, bend your knees and keep them aligned with hips.

**Position B:** as you exhale, slowly lift your chest up; as you inhale, slowly lower your chest down. Avoid bringing your chin to your chest. **Sets:** 3

Repetitions: 12

Name: Standing calf raises Type: Isotonic Position A: Standing on both legs, hands on the wall for balance (if needed). Position B: rise up on toes then slowly lower down. Sets: 3 Repetitions: 12

## **Conditioning PHASE 2**

В

Α







Name: Plank Type: Isometric Position A: lying on your belly (prone position). Position B: lift your entire body up with elbow and feet supports. Hold for 15 up to 30 seconds. Sets: 3 x 15-30 seconds

## Name: Bridge with one leg Type: Isometric

**Position A:** lie down on the mat, knees pointing to the ceiling, knees aligned with hips.

**Position B:** raise your hips up toward the ceiling then carefully take one leg off the floor. Hold for 15 up to 30 s. **Sets:** 3 x 15-30 seconds

# **SUPPLEMENTARY FILE**

В

60



Α











Name: Clam shell Type: Isotonic Position A: side lying position, elastic band around your thighs, knees bent. Position B: move your knee away, squeezing your buttocks then slowly return. Repeat with the other side/leg. Sets: 3

## Repetitions: 12

Name: Abdominal curls with lifted legs

## **Type: Isotonic**

Position A: lie down on the mat, place your hands behind your head, bend your knees and keep them aligned with hips. Lift both legs up.
Position B: as you exhale, slowly lift your chest up; as you inhale, slowly lower your chest down. Avoid bringing your chin to your chest.
Sets: 3

Repetitions: 12

## Name: Trunk extension Type: Isometric Position A: lying on your belly (prone position). Position B: move your chest away from the floor. Look at the ground. Hold for 30 seconds at least. Repetitions: 3 x 30 seconds

## Name: Wall squat

Type: Isometric contraction Position A: stand with your trunk to a wall, feet aligned with knees and hips, and away from the wall. Position B: slide down and keep your trunk towards the wall. Hold for 30 seconds up to one minute. Repetitions: 3

## Name: Partial squat Type: isotonic contraction Position A: standing on both legs. Position B: slowly bend your knees and stand up again. Maintain your knees over your feet. Repetitions: 3







## **SUPPLEMENTARY FILE**



Α



В













Name: Standing hip abduction. Type: static balance Position A: standing on both legs with an elastic band around both legs. Position B: lift one leg out, maintain the kneecap pointing forward, and hold for 30 seconds or more. Repetitions: 3 (each leg)

Name: Standing on one leg Type: static balance on stable surface Position A: standing on both legs, eyes opened.

**Position B:** standing on one leg, knee slightly bent, lift the other leg off the floor and maintain the position up to 1 minute.

Repetitions: 2 (each leg)

Name: Standing on one leg Type: static balance on unstable surface (trampoline, foam etc) Position A: standing on both legs, eyes opened. Position B: standing on one leg,

remove another leg from ground and maintain the position. **Repetitions:** 2 (each leg)

#### Name: Step-up

Type: isotonic contraction Position A: on leg onto a step. Position B: step up onto the next step, use the wall for balance if needed. Step back down carefully to the position A. Sets: 2 (each leg) Repetitions: 12

BMJ Open



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item Item No		Description
Administrative in	format	ion
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym – <b>PAGE 01</b>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry <mark>– PAGE 02</mark>
	2b	All items from the World Health Organization Trial Registration Data Set - N/A
Protocol version	3	Date and version identifier <mark>- N/A</mark>
Funding	4	Sources and types of financial, material, and other support - PAGE 14
Roles and	5a	Names, affiliations, and roles of protocol contributors – PAGE 01
responsibilities	5b	Name and contact information for the trial sponsor - N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities - N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) - N/A
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention – PAGES 4-5
	6b	Explanation for choice of comparators – PAGES 4-5
Objectives	7	Specific objectives or hypotheses – PAGES 4-5

Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework superiority, equivalence, noninferiority, exploratory) – PAGE 6
Methods: Particip	oants,	interventions, and outcomes
Study setting	9	Description of study settings (eg, community clinic, academic hosp and list of countries where data will be collected. Reference to whe list of study sites can be obtained <mark>– PAGE 6</mark>
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligib criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) – PAGE 7
Interventions	11a	Interventions for each group with sufficient detail to allow replicatio including how and when they will be administered <b>– PAGES 8-10</b>
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) – PAGES 8-1
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) – PAGES 8-10
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial – <b>PAGES 8-10</b>
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy a harm outcomes is strongly recommended <b>– PAGES 10-11</b>
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins a washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) – PAGE 22
Sample size	14	Estimated number of participants needed to achieve study objective and how it was determined, including clinical and statistical assumptions supporting any sample size calculations – PAGE 12
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size - PAGE 7

_			
1 2 3 4 5 6 7 8 9	Sequence generation	16a	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions – PAGE 12
10 11 12 13 14	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned - PAGE 12
15 16 17	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions – PAGE 12
18 19 20 21 22	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how – PAGES 8, 10
23 24 25 26		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial – N/A
27 28	Methods: Data co	llectio	n, management, and analysis
29 30 31 32 33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol <b>– PAGES 12-13</b>
37 38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols – PAGES 12-13
42 43 44 45 46 47 48	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol – PAGE 12-13
49 50 51 52	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol – PAGES 12-13
53 54 55 56		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses) <mark>– PAGES 12-13</mark>
50 57 58 59 60		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) – PAGES 12-13

1 2 3 4 5	
6 7 8 9 10	
11 12 13 14 15 16	
17 18 19 20 21	
22 23 24 25 26 27	
28 29 30 31 32	
33 34 35 36 37	
38 39 40 41 42 43	
44 45 46 47 48	
49 50 51 52 53 54	
55 56 57 58 59	
60	

Methods: Monito	ring	
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed N/A
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial – N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct – <b>PAGES 6-8</b>
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor – N/A
Ethics and disser	minatio	on
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval <mark>– PAGES 13, 14</mark>
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) – PAGE 13
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) – PAGE 13
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial <b>– PAGES 06, 07</b>
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site <mark>– PAGE 14</mark>
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators <b>N/A</b>
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation N/A

2 3 4 5 6	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions –
7 8			PAGES 13, 14
9 10 11		31b	Authorship eligibility guidelines and any intended use of professional writers N/A
12 13 14		31c	Plans, if any, for granting public access to the full protocol, participant- level dataset, and statistical code – PAGE S13, 14
15 16	Appendices		
17 18 19	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates <b>N/A</b>
20 21 22 23 24	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable N/A
24 25	*It is strongly recor	nmenc	led that this checklist be read in conjunction with the SPIRIT 2013

It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.